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Abstract
Both cancer and autoimmune diseases have been associated with numerous factors that
may independently lead to the development of either disease. When these factors overlap
the difficulty in assessing association is compounded. The numerous factors that are
thought to cause systemic lupus erythematosus (SLE), which leads to the development of
cancer, makes the study of an association between the 2 diseases challenging. The
purpose of this study was to examine whether the risk of cancer development increased in
SLE patients compared to the risk in non-SLE patients. Researchers have not shown
consistent relationships of cancer development in patients with SLE; however,
consideration of the various factors that contribute to the diseases is necessary to measure
an association between the 2 diseases. This study used the Clinical Practice Research
database (CPRD), a large, population-based database to test the relationship between SLE
and cancer. A matched retrospective cohort study among SLE (n=3025) and non-SLE
(n=180555) patients was conducted using the propensity score methodology to help
balance the differences between the comparison groups. The propensity score
methodology created a similar distribution of observed baseline covariates between the 2
groups. With adjustment for age, the predictor variable of SLE indicates that a patient
with SLE is still 2.7 times more likely to develop cancer than is a non-SLE patient. The
study outcomes could promote positive social change by reinforcing current
recommendations for cancer screenings in persons with SLE, which could enhance the
ability to detect cancer early enough to decrease mortality because of cancer in persons
with SLE.
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Chapter 1: Introduction to the Study
Introduction
Systemic lupus erythematosus (SLE) has accounted for a significant number of
deaths because of the devastation that this disease causes on numerous organ systems of
the body. SLE disease activity is better understood and is controlled with the use of
medications (Liang et al., 2012). The control of SLE flares has resulted in decreased
deaths due to SLE activity, and people affected by the disease are living longer that they
did 25 years ago (Liang et al., 2012). However, the increase in the lifespan of people with
SLE has led researchers to determine that other chronic diseases are often the cause of
death for persons with SLE (Liang et al., 2012).
People with SLE are more likely to be diagnosed with certain types of cancer as
compared to persons without SLE (Bernatsky et al., 2005; Kiss, Kovacs, & Szodoray,
2010; Parikh-Patel, White, Allen, & Cress, 2008). Several risk factors have been
proposed to account for the increased development of cancer among persons with SLE,
including the use of immunosuppressive agents that increases the development of
malignancies (Bernatsky, Ramsey-Goldman, & Clarke, 2006). Other risk factors that may
increase the incidence of cancer in people with SLE include genetic predisposition,
lifestyle-related risk factors, and abnormalities in cell death regulation (Kiss et al., 2010;
Tincani, Taraborelli, & Cattaneo, 2010; Schultz & Harrington, 2003). In this study, I
assessed the rate of cancer in patients with SLE compared to patients without SLE.
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The results of this study may provide a better understanding of cancer
development in people with SLE. The results did reveal a greater association of cancer
development in patients with SLE as compared to non-SLE patients. The study outcomes
could promote positive social change by reinforcing current recommendations for cancer
screenings particularly in persons with SLE. Stronger adherence to cancer screening
recommendations could enhance the ability to detect a cancer early enough so that
treatment can be implemented that may result in a higher likelihood of eradicating the
cancer and decreasing mortality due to cancer in persons with SLE. The results from this
study may also equip persons with SLE with scientifically based knowledge that may
enable them to make decisions regarding their care with a clearer understanding of the
cancer risks inherent to persons with SLE, particularly when factored with their
knowledge of their personal familial risks for cancer development.
In this chapter, literature related to cancer development in persons with SLE is
summarized to identify gaps in current knowledge. The significance of whether an
association in cancer development exists in persons with SLE is presented. A discussion
of the purpose of the study, research questions, and the theoretical framework for the
study are presented. Both dependent and independent variables and their definitions are
provided. The research problem addressed and the limitations of the study are described
in this section. The chapter concludes with potential contributions that this study will
make toward the body of scientific knowledge, medical practice, and positive social
change.
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Background
Several risk factors for the development of cancer among persons with SLE have
been proposed that would support an increased risk of cancer in this population, but these
risks have not been fully explored. Both SLE and cancer have etiologic agents in
common. In assessing the association of cancer in autoimmune diseases, many of the
treatments used for the treatment of autoimmune diseases have been associated with the
development of cancer (Azab et al., 2008). In addition, both cancer and autoimmune
diseases have been associated with diet, air quality, exposure to certain drugs, and
personal habits, which makes the study of an association between the two diseases
challenging. Bei, Masuelli, Palumbo, Modesti, and Modesti (2009) concluded that the
interaction between autoantibodies in cancer patients and autoimmune patients have
similar antibodies that must be considered because they can change the properties of each
other and impact the growth and progression of each disease. SLE is an autoimmune
disease that results when the body starts to produce antibodies against itself. Signaling
between antibodies (T cells and B cells) is impaired. Both T cells and B cells are
instrumental in the development of several cancers. The interaction of these two
antibodies must be considered because the properties of each are interdependent, as
concluded by Bei et al. (2009).
Researchers have not consistently shown positive relationships between cancer
development and SLE. Some scholars have shown that an increased risk of hematological
cancers in SLE patients is likely because of other causes such as medications (Bernatsky
et al., 2008). An understanding of the effects of the various factors that contribute to a
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disease is necessary to measure an association of the variable to disease development
(Broadbent, 2009). Because autoimmune diseases, such as SLE, have several risk factors
that are thought to cause the disease, a more definitive association of the proposed causes
of SLE are needed to measure better the association of the SLE risk factors in cancer
development. The use of the high dimensional propensity model in this study balanced
the two cohorts, so that a better assessment of the selected risk factors can be conducted.
Previous studies conducted have concluded that cancer rates are increased in SLE
patients. The previous studies have shown variability in which types of cancers have been
found to be increased. Kiss et al. (2010) identified several malignancies, such as nonHodgkin’s lymphoma (NHL), cervical cancer, and bronchial carcinomas, that were found
to be increased in SLE patients, with the highest risk occurring in the first year of disease
diagnosis. Nived, Bengtsson, Jönsen, Sturfel, and Olsson (2001) followed SLE patients to
determine the rate of new malignancies following initial SLE diagnosis. Parikh-Patel et
al. (2008) proposed that patients with SLE have an increased risk of developing
hematologic, kidney, and thyroid cancers. Hildalgo-Conde et al. (2013) suggested that the
incidence of cancer was four times greater than expected in a cohort study of Spanish
patients. As shown by the findings from these studies, there is variability in the types of
cancers that have been found to have an increased incidence in SLE patients.
Most studies conducted to assess the association of cancer development in
patients with SLE have been relatively small in size; therefore, the researchers have been
unable adequately to examine the development and exposures of cancers, especially those
that are not common (Bernatsky et al., 2008). In this study, consideration was given to
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the multiple factors that play a role in the development of SLE and in cancer. A large,
population-based database was used to assess the relationship between SLE and cancer in
a large population. The larger sample size in this study allowed cancers that occur at a
lower incidence to be examined. Finally, I examined the incidence rates of various cancer
types found in patients with SLE. The design of the study and the methods to assess the
findings were dynamic enough to allow for a more detailed analysis that could be easily
understood.
Researchers have shown inconsistent relationships between cancer development
and SLE. The positive associations between hematologic cancers and several
autoimmune diseases have been demonstrated in several studies. Bernatsky et al. (2008)
studied immunosuppressive therapy in SLE patients and found that immunosuppressive
therapy may not be the principle driving factor for overall cancer risk, but may contribute
to an increased risk of hematological cancers and is likely a plethora of causes that result
in cancer development in persons with SLE. Kiss et al. (2010) identified that several
malignancies, such as NHL, cervical cancer, and bronchial carcinomas, are found at a
higher rate in patients with SLE; in addition, SLE patients have an increased incidence
and risk of cancer development, with the highest risk occurring in the first year of disease
diagnosis. Nived et al. (2001) followed SLE patients to determine the rate of new
malignancies following initial SLE diagnosis. Interestingly, Nived et al. did not find an
overall increase in the cancer in SLE patients but did find increased frequencies of NHL.
Although the etiology of autoimmune disorders is not known with certainty,
several hypotheses have been proposed to explain the reason for the body to begin
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attacking itself. Nakazawa (2008) described environmental triggers, such as chemicals,
drugs, hormones, infections, stress, hormones, behaviors, and diet that are thought to
cause the body to start producing antibodies against itself. Because a high number of
autoimmune diseases, such as SLE, are more prevalent in females, hormones may
contribute to the development of autoimmunity. Approximately 78% to 90% of people
with SLE are women (Fairweather & Rose, 2004). Because such a high percentage of
women who develop SLE are women, the activities of hormones, such as estrogen, a
hormone that has higher levels in women, should be acknowledged in an assessment of
cancer development in SLE patients. Estrogen is also considered a risk factor for cancers
such as breast cancer.
Immunosuppressive therapy is a common treatment for SLE. This therapy is
implemented to suppress the immunology system and decrease a reaction to the
production of the antibodies that the body is producing against itself. Bernatsky et al.
(2008) proposed that immunosuppressive medications used to treat SLE may not be the
main factor for overall cancer risk in SLE patients. Immunosuppressive medications may
contribute to an increased risk of developing hematologic cancers, and future scholars
should evaluate other factors that increase the risk for malignancy in persons with SLE.
Chang et al. (2005) found that the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
to treat inflammation increased the risk of NHL. Engels et al. (2005) found Sjögren’s
syndrome to have the strongest association with immune-related conditions and immune
modulating medications as risk factors for NHL. Although SLE is different from
Sjögren’s syndrome, they are both autoimmune diseases and have some similarities.
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Findings from studies of other autoimmune diseases, such as Sjögren’s syndrome, must
be considered when studying SLE as in this study because of the similar risk factors and
treatments.
There are variable relationships between cancer developments in patients with
SLE (Bernatsky et al., 2008; Kiss et al., 2010; Parikh-Patel et al., 2008). The smaller
sample sizes of previous studies have not allowed for an examination of cancers that are
diagnosed at a lower incidence, which is important because of the various associated risk
factors, etiology, and pathophysiology of cancers that occur less frequently. There is a
gap in the current literature on the association between cancer development and SLE, and
it is not known if there is an increased incidence of cancer development in persons with
SLE.
Problem Statement
Chronic non-communicable diseases (CNCDs), such as SLE, account for a
significant number of deaths, which are often a result of the impact of SLE on various
organ systems (Manzi, 2009). However, the increased control of SLE disease activity has
allowed researchers to study other areas of concern relative to persons with SLE (Manzi,
2009). In this study, I assessed the association between cancer and SLE.
Various types of cancer (including NHLs, cervical cancer, and lung cancer) are
more prevalent in patients with SLE as compared to persons without SLE (Bernatsky et
al., 2005; Kiss et al., 2010; Parikh-Patel et al., 2008). Researchers have proposed several
risk factors that may lead to higher rates of cancer in persons with SLE, such as the use of
immunosuppressive agents, which has been determined to be a carcinogen (Bernatsky et

8
al., 2006). Other risk factors that have been suggested, although not fully explored,
include genetic predisposition such as the presence of antiphospholipid antibodies (which
are frequently present in persons with both SLE and cancer), lifestyle-related risk factors
such as smoking, and abnormalities in cell death regulation (Kiss et al., 2010; Tincani et
al., 2010; Schultz & Harrington, 2003). However, it is uncertain whether SLE is
associated with a higher rate of cancer (Bernatsky et al., 2005).
Previous research in assessing cancer development in patients with SLE has been
based upon small study samples and cohorts that were not closed, which could increase
the number of patients lost to follow-up. These studies lacked definitive diagnosis dates
for SLE in the participants (Bernatsky et al., 2005; Parikh-Patel et al., 2008). As a result,
previous studies were underpowered, and the scholars were unable to determine
conclusively whether a relationship exists between SLE and cancer (Bernatsky et al.,
2005). Moreover, the smaller sample sizes did not permit those diagnosed at a lower
incidence to be assessed because there are many risk factors associated with cancer
development associated with cancers that do not occur at a high frequency. This study
used a large, population-based database to test the relationship between SLE and cancer.
The larger sample size in this study allowed cancers that occur at a lower incidence to be
examined. Finally, I examined the incidence rate of cervical cancer in patients with SLE.
Purpose of the Study
A propensity, score-matched, retrospective cohort study among SLE and non-SLE
female patients identified in the CPRD was used to assess the association between cancer
development and SLE. Female SLE patients with prevalent and/or incident cases were

9
included in the study. Non-SLE patients were matched with SLE patients in CPRD. The
patients were then linked to an additional database for information on covariates. The
cohort design was most suitable for this study to take advantage of all available data in
the secondary data sources, to allow multiple outcomes to be examined, causality to be
assessed, and to allow for the calculation of disease rates in the exposed and unexposed
patients (Song & Chung, 2010).
The main exposure was SLE and non-SLE (unexposed), and study patients were
designated as SLE or non-SLE. Both prevalent and incident cases were included in the
analysis. The outcome was overall incidence of cancer and incident of cervical cancer.
Cancer diagnoses were identified in CPRD (Health & Social Care Information Center.
2014). Incident cases included cases in which cancer was first diagnosed after the index
date in people with at least 12 months of registration in CPRD. The first diagnosis of
each cancer type was used in instances where the person had multiple cancer diagnoses at
different times.
Data on covariates came from CPRD and HES. Information relating to SLE
flares, number of hospitalizations, treatment, diagnoses, and medications came from
HES. Each SLE patient was matched to non-SLE patients using variables to determine
the probability of developing SLE (p [SLE]) in the patients. Balance between the exposed
(SLE) and non-exposed (non-SLE) cohorts was obtained by using variables that were
associated with the development of SLE to determine the treatment and non-treatment
cohorts. This method of cohort selection was used to balance the SLE causing variables
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in the cohorts. The control of the number and similarity of variables in the patients in
each cohort kept the variables balanced between the study participants.
Research Questions and Hypotheses
RQ1: Is the risk of cancer development increased in SLE patients compared to non-SLE
patients?
H01: There is no increased risk of cancer development in SLE patients compared to nonSLE patients for overall cancer risk and cervical cancer risk.
Ha1: There is an increased risk of cancer development in SLE patients compared to nonSLE patients for overall cancer risk and cervical cancer risk.
Theoretical Framework
The disease causation theory was the conceptual framework for this study. In this
study, I assessed the association between cancer and SLE as compared to rates of cancer
in non-SLE patients. There are many challenges in determining associations, especially in
chronic diseases such as SLE and cancer. These two diseases involve multiple factors that
interact and result in their disease state. The complexity of these two CNCDs led to the
selection of a multifactorial causation theory as the basis for this study. The basic
components of the multifactorial framework are that diseases have many causes, which
cannot be independently attributed as the sole causative agent (Broadbent, 2009). The
multifactorial framework was relevant for this study because of the multiple agents that
have been proposed to cause SLE and to cause cancer, and because disease activity in
SLE can contribute to an increased risk of cancer development.
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The disease causation theory has been used to explain CNCDs such as diabetes,
cancers, and autoimmune diseases (Najman, 1980). Unlike communicable diseases that
can be attributed to a microorganism, these diseases do not originate from an organism,
nor are they transmitted communicably. These factors of origination and method of
transmission disqualify these diseases from being explained by the mono-causal model of
disease that was applicable to communicable infectious diseases prevalent in the 19th
century (Najman, 1980). Whereas diseases, such as smallpox, could be traced to a
causative organism, diseases such as SLE and cancer cannot be traced to a single
causative organism; these diseases are proposed to be caused by multiple factors such as
environment, genetics, lifestyle choices, and possible organisms that result in the disease
state (Broadbent, 2009). These multiple factors may explain the development of these
diseases although no single factor by itself leads to the development of cancer or
autoimmune diseases. The multifactorial disease causation theory was used as the
foundation of this study because both SLE and cancers are the result of the occurrence of
multiple factors.
Nature of the Study
A matched, retrospective, cohort study among SLE and non-SLE patients
identified in the CPRD was used to assess the association of cancer development in
patients with SLE. SLE patients with prevalent and/or incident cases were included in the
study. Non-SLE patients were matched with SLE patients (4 to 1) on age, gender,
practice, and date of registration in the CPRD. The patients were linked to the death
registry for death due to cancer and to the HES database for data on some covariates (see
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Table 1). The cohort design is most suitable for this study to take advantage of all
available data in the secondary data sources, the CPRD, and the death registry. The
cohort design allowed for multiple outcomes to be examined, causality to be assessed,
and rare cancer exposures to be investigated. This design allowed for the calculation of
disease rates in the exposed and unexposed patients (Song & Chung, 2010).
Table 1
Definitions
Variable
Age
(independent)
Female
(independent)
Immunocompromising
Treatment (independent)
Active Disease
(independent)

Cancer Development
(dependent)

Definition
Number of years a patient has
been alive
Male or Female
Medications that cause the
body’s immune system to be
compromised
Diagnosis of SLE as per
American College of
Rheumatology (ACR) or No
diagnosis of SLE has been
made
Diagnosis of a cancer

How Measured
Numerical
Categorical
(M=0; F=1)
Numerical

Categorical
(Severe or Mild)

Categorical

The methodology used was quantitative, and the design was a high-dimensional
propensity model. The main exposure was SLE (exposed), and study patients who did not
have SLE were designated as SLE or non-SLE. Both prevalent and incident cases were
included in the analysis. The outcome was cancer overall and cervical cancer in
particular. Malignant cancer diagnoses were identified in CPRD, HES, and the death
registry (for cause of death due to cancer). Incident cases included cases in which cancer
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was first diagnosed after the index date in people with at least 12 months of registration
in CPRD. The first diagnosis of each cancer type was used in instances where the person
had multiple cancer diagnoses at different times.
Disease severity was measured by the use of IC treatment, along with other
treatments such as NSAID and antimalarial drugs, which can be a proxy for disease
activity and was considered a time dependent variable. A level of disease severity (e.g.,
mild, severe) was assigned based upon the number of comorbidities, number of
hospitalizations, severe complications (e.g., renal transplantation), and use of IC
treatments. The definition of this variable depended on what was available in the
database.
Assumptions
Assumptions critical to the meaningfulness of this study that could not be
demonstrated to be true included that data entered into the CPRD were accurate. The
CPRD has been noted as having a high rate of data entry by the practitioners and was
used in several studies for this reason. It was also assumed that patients diagnosed with
SLE were accurately diagnosed, and the non-SLE patient did not have SLE.
Scope and Delimitations
An increase in life expectancy for persons with SLE has resulted in the
recognition of other chronic diseases as cause for death in patients with SLE. Previous
studies of cancer development in SLE patients have speculated that medications
commonly used to treat SLE may be contributing factors. This study assessed whether the
risk of cancer development was increased in SLE patients compared to non-SLE patients.
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I chose to focus on overall cancer development and cervical cancer in particular. The
cohorts consist of women only, which is the reason that cervical cancer was focused upon
in this study. I specifically chose to not focus on cancers that have a higher incidence in
the male population because only women will be included in this study. By focusing on
overall cancer development and cervical cancer development in women, the findings are
generalizable to women with SLE.
Limitations
The validity of this study depended on the accuracy and reliability of the
information entered into the database. SLE is a difficult diagnosis to make, and there may
have been a risk of including non-SLE patients. I excluded cases that were diagnosed
within 6 months because both SLE and some cancers may have similar symptoms, and it
may not be clear which diagnosis preceded the other. This scenario may threaten the
validity of the study by possibly including patients who were inaccurately diagnosed with
SLE or who had not been diagnosed with SLE when they should have been.
In a clinical study, bias refers to any errors in the study (Gerhard, 2008). The
identification of bias or potential bias in a study allows the researcher to include steps
that can assist in counteracting areas of bias. The most common areas of bias occurred in
the history of the patients admitted into the study, the inclusion criterion used to select
patients into the study, and the methods used to analyze the study results (Gerhard, 2008).
The study population included females with SLE and matched female non-SLE
patients. Patients with a diagnosis of SLE were matched to non-SLE females using
propensity scores that are based on SLE risk factors. This method of matching the
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patients by using risk factors associated with SLE was one method to address bias that
can enter a study by using the history of the patients in the comparison groups. Risk
factors associated with the development of SLE were used to select the participants in
both comparison groups. This matching decreased bias due to the selection process. A
lack of consideration of the history of the patients, especially those factors that could lead
to the development of SLE, could create bias between the comparison groups. The
propensity score method of matching also addressed bias that is commonly a result of
inclusion and exclusion criterion for a study. Selection using propensity score matching
ensured that the comparison groups were equal in their covariates that could lead to the
development of SLE and cancer.
Limitations are inevitable in research. CPRD is a combined effort of the MHRA’s
General Practice Research Database (GPRD) and the Department of Health’s NIHR
Research Capability Program (RCP) into a secure electronic research database. The use
of data that have already been collected has limitations in that the research questions must
be tailored around the information that is available in the database. An additional
limitation associated with using CPRD is that I am not sure if the data were entered into
the database with accuracy and reliability. CPRD does have the ability to be linked to
other major databases such as the United Kingdom and Ireland Association of Cancer
Registries (UKIACR) at a cost. The lack of funds to have CPRD linked with the
UKIACR created another limitation in that the source of the most comprehensive data on
cancer was not used in the study. The HES database was used because the UKIACR
database could not be linked in this study.
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Significance
Better control of SLE flares has resulted in fewer deaths caused by disease
activity in this population of patients. Chronic diseases such as cancers have now been
shown to be causes of death in patients with SLE. Current cancer screening
recommendations for SLE patients may not be enforced enough to encourage patients to
adhere to them. It is necessary to understand the association of cancer development in
patients with SLE to create positive social change, which will support adherence of
cancer screening recommendations.
Previous studies on the association of cancer development in patients with SLE
have shown variable outcomes. Because several of the previous studies have been small
and the comparison groups did not seem to be balanced as far as exposure to risk factors
associated with SLE and cancer development, this study included a large population and
balanced the cohorts based upon risk factors of SLE and cancer. The larger size of this
study resulted in results that are generalizable. The study design, a high dimensional
propensity model, allowed the patients to be balanced based on their exposure to
medications and other diseases. This balance is significant because of the many factors
that have been found in previous studies to contribute to chronic diseases such as cancer.
Summary
As discussed in this chapter, persons diagnosed with SLE are being diagnosed
earlier, which has resulted in the use of medications that decrease the devastation cause to
body organs because of flares. These factors have resulted in persons with SLE living
longer than they did 25 years ago. This increase in lifespan has allowed researchers to
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find that patients with SLE are now having chronic diseases such as cancer to cause
mortality in SLE patients. Several studies have been conducted to assess the association
of cancer development in patients with SLE, but many of the studies had a small study
population and the results have had variability in the findings. My study used a large
population-based database, the CPRD, to assess that association of cancer development in
SLE patients. The large study population and the use of a high dimensional propensity
model to select the cohorts resulted in cohorts that were balanced in terms of medications
used and concurrent diagnoses experienced in patients in each of the cohorts. The balance
of the cohorts in this study, because of the use of a high dimensional propensity model,
allowed an equitable assessment of cancer development in patients with SLE.
In Chapter 2, a synopsis of the current literature on the problem will be presented
with the strategy used to research the literature and a literature review of key elements
related to concepts, variables, and methodology. A description of how the present study
fills the gaps in the literature and how the results of this study will extend knowledge in
the discipline will also be presented.
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Chapter 2: Literature Review
Introduction
CNCDs such as SLE account for a significant number of deaths (Manzi, 2009).
Persons with SLE are 2.4 times more likely to die of any cause than a non- SLE person
after adjusting for demographic characteristics (Bernatsky, 2006). SLE is difficult to
diagnose because it involves multiple organ systems, and it has no single diagnostic
marker; rather, several different clinical symptoms and laboratory values must be
combined eventually to diagnose the disease (Gill, Quisel, Rocca, & Walters, 2003).
Diagnosis of SLE is made after the patient has exhibited 4 of 11 clinical symptoms and/or
laboratory criteria. The average person with an autoimmune disease has a lifespan
shortened by 15 years, and autoimmune diseases are the eighth leading cause of death
among females (Nakazawa, 2008). The difficulty is diagnosing SLE and the impact of the
lifespan has a significant economic impact of the public health system.
As previously stated, the economic burden caused by autoimmune diseases makes
them a public health concern. The health care burden is estimated at approximately $120
billion, compared to $70 billion for cancer (Nakazawa, 2008). Additional burdens are
placed on the health care system because of multiple trips to health care professionals in
an attempt get an accurate diagnosis. In addition, patients with autoimmune diseases
often face a poor quality of life that includes physical changes in their appearance (i.e.,
hair loss, facial rashes, loss of job, and/or eventual disability status) (Bertsia, Cervera, &
Boumpas, 2012). The control of SLE flares has decreased the damage on organ systems
in the body, which has resulted in decreased deaths due to SLE activity; this increased
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control of SLE disease activity has now allowed researchers to study other areas of
concern relative to persons with SLE (Manzi, 2009). In this study, I assessed the
association of malignancies in persons with SLE.
Various types of cancer, including NHLs, cervical cancer, and lung cancer,
increase in patients with SLE as compared to persons without SLE (Bernatsky et al.,
2005; Kiss et al., 2010; Parikh-Patel et al., 2008). Interestingly, people with SLE were
also found to be less likely to die of cancer (except for NHL and lung cancer) as
compared to non-SLE persons (Bernatsky et al., 2006). Persons with SLE had a SMR of
2.8 for NHL and a SMR of 2.3 for lung cancer (Bernatsky et al., 2006).
Researchers have proposed several risk factors for the development of cancer
among persons with SLE that would support an increased risk of cancer in this
population, including the use of immunosuppressive agents, which increases the
development of malignancies (Bernatsky et al., 2006). Other risk factors that have been
suggested, although not fully explored, include genetic predisposition such as the
presence of anti-phospholipid antibodies, which are frequently present in persons with
both SLE and cancer; lifestyle-related risk factors such as smoking; and abnormalities in
cell death regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2010).
However, whether or not SLE is associated with a higher rate of cancer is uncertain
(Bernatsky et al., 2005). Previous research in this area has been based upon small study
samples and cohorts that were not closed, which could increase the number of patients
lost to follow-up, and the studies have lacked definitive diagnosis dates for SLE in the
participants (Bernatsky et al., 2005; Parikh-Patel et al., 2008). As a result, previous
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studies were generally underpowered to determine conclusively whether a relationship
exists between SLE and cancer (Bernatsky et al., 2005). Moreover, the smaller sample
sizes did not permit an examination of cancers that are diagnosed at a lower incidence,
which is important because of the various associated risk factors, etiology, and
pathophysiology of cancers that occur less frequently. This study used a large,
population-based database to test the relationship between SLE and cancer in a large
population. The larger sample size in this study allowed cancers that occur at a lower
incidence to be examined. Finally, this study examined the incidence rates of various
cancer types found in patients with SLE.
In this chapter, a discussion of literature on the pathogenesis of SLE and of cancer
will be reviewed, followed by highlights of etiological similarities between the two
chronic diseases. In addition, other autoimmune diseases that have established
associations to specific cancers will be highlighted. I will then provide a review of
literature written and based upon completed studies on the association between cancer
and SLE with a focus on the types of cancers that have been found to have an increase in
incidence in those studies. Finally, a review of literature on the medications used to treat
SLE will be discussed.
Literature Search Strategy
The literature review should consist of studies that are similar to the research
topic (Creswell, 2009). The literature contained in this review was used to establish a
relationship with my study to research that has already been conducted. The principle
source for obtaining the sources for the literature review was the MedImmune Corporate
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Library. The MedImmune Corporate Library allows access to multiple electronic
resources such as e-journals (greater than 12,000), online books (greater than 7,000), and
dozens of databases such as Biosis, Embase, Medline/PubMed, SciFinder, Scopus, and
Web of Science. The Walden University Library EBSCO databases were also used for
literature searches. Other databases that were accessed included the Cumulative Index to
Nursing & Allied Health Literature (CINAHL), MEDLINE, and ProQuest. Governmental
Web sites, such as the U.S. Centers for Disease Control and Prevention (CDC) and the
Medicines and Healthcare Products Regulatory Agencies (MHRA), were also used.
Strategies used when searching for and identifying articles for this literature
review included the use of key words to search for articles (see Table 2). Key words and
word combinations used to conduct searches included systemic lupus erythematosus,
autoimmune diseases, cancer and autoimmune diseases, malignancies, cancer
development, and autoimmunity. Once I found the articles, I reviewed the abstracts and
read through the articles to determine if they would make a contribution to my
understanding of the research topic. I also used guides to terms to locate articles
(Creswell, 2009). Using multiple resources and databases allowed me to find several
literature articles that were useful in this research project.
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Table 2
Search Terms and Combinations for Literature
Topic(s)
Theory

Key words
theories

SLE etiology

systemic lupus
erythematosus
SLE
Lupus
cancer
malignancy
lymphomas

cancer etiology

common links
incidence of cancer
cancer development

drugs and cancer

lupus treatments

Combinations
chronic disease theories
causation theory
lupus & autoimmunity
lupus pathogenesis

cancer pathogenesis

cancer & SLE
lupus & cancer
lymphomas in lupus
auto antibodies in cancer
and lupus
cancer in lupus

Articles published within 10 years of data collection were included in the study,
unless there was limited information or published research on the topic or the research
had a significant impact on the scientific body of knowledge of cancer or autoimmunity. I
retrieved approximately 200 articles of which approximately 100 were found to be related
to my study. Several articles were eliminated because the date of publication was greater
than 10 years. Other articles were eliminated because the results appeared to be biased, or
the journals were not peer-reviewed.
Theoretical Foundation
Because both SLE and cancer have a plethora of proposed causes, the disease
causation theory served as framework for this study. The disease causation theory
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proposes that diseases have many causes, which cannot be independently attributed as a
sole causative agent (Broadbent, 2009). This multifactorial framework served as a basis
to assess the use of immunosuppressive therapies and cancer development in persons
with SLE. This framework also served to assess the development of specific types of
cancers, such as cervical cancer and lung cancer in persons with SLE.
The disease causation theory was used to build the conceptual framework for this
study. This study assessed the association of malignancy in patients with SLE. There are
many challenges in determining associations especially in chronic diseases such as cancer
and SLE. These two diseases involve multiple factors that interact and result in their
disease state. The complexity of these two CNCDs resulted in the selection of a
multifactorial causation theory as the basis of this study. The basic components of the
multifactorial framework are that diseases have many causes, which cannot be
independently attributed as the sole causative agent (Broadbent, 2009). The multifactorial
framework was most relevant for this study because of the use of immune compromising
treatments for SLE treatment and disease activity in SLE can both contribute to increased
risk of cancer development.
The disease causation theory has been applied to explain CNCDs such as
diabetes, cancers, and autoimmune diseases. Unlike communicable diseases that can be
attributed to a specific microorganism, these diseases do not originate from an organism,
nor are they transmitted communicably. These factors of origination and method of
transmission disqualify these diseases from being explained by the mono-causal model of
disease that was very applicable to communicable infectious diseases that were so
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prevalent in the nineteenth century. Whereas diseases such as smallpox could be traced to
a causative organism, diseases such as SLE and cancer cannot be traced to a single
causative organism, but are proposed to be caused by multiple factors such as
environment, genetics, lifestyle choices, and possible organisms that result in the disease
state. These multiple factors together may explain the development of these diseases
although no single factor by itself leads to the development of cancer or several of the
autoimmune diseases. The multifactorial disease causation theory was used as the
foundation of this study because both SLE and cancers are the result of the occurrence of
multiple factors.
Etiology of SLE
SLE is a chronic inflammatory autoimmune disorder that occurs when the body’s
immune system attacks its own tissues and organs. An overactive immune response by
the body against substances and tissues that are in the body, along with an inability to
tolerate self-antigens, characterize the development of autoimmune diseases (Cristaldi,
Malaguarnera, Rando, & Malaguarnera, 2011). Nagy, Koncz, and Perl (2005) described
the etiology of SLE as a decrease in tolerance to self-antigens with polyclonal activation
of B lymphocytes, production of different autoantibodies, and alteration in the function of
T cells. This alteration in the T cells impacts T cell homeostasis and the modulation of
immune responses to allergens, cancer cells, and pathogens (Belkaid, Piccirillo, Mendez,
Shevach, & Sacks, 2002). SLE could be summarized as an immune response against
internal nuclear antigens, which have been released from cells that were programmed to
die but have been reactivated because they were presented to T cells. The reactivation of
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these cells results in the production of helping B cells, which produce autoantibodies and
secrete cytokines (regulatory proteins) that interact with cells of the immune system to
mediate the immune response (Bertsias et al., 2012).
Etiology of Cancer
Cancer is a broad term that describes more than 100 diseases in which cell
division gets out of control and invades other tissues in the body by spreading via the
blood and/or lymphatic systems (National Cancer Institute [NCI], 2014). The body is
composed of cells that grow, divide, and die; they are then replaced with new cells.
However, cancer occurs when the cells genetic material gets damaged and the cells stop
the normal cycle of dying, and their growth gets out of control (NCI, 2014). Damaged
genetic materials of cells produce mutations, which affect normal cell growth (Bertsias et
al., 2012). Cancers can either spread to other areas of the body (metastatic), or it can be
contained in just one area of the body (benign). In 1999, cancer replaced heart disease as
the leading cause of death among men and women 85 years of age and younger (Siegel,
Ward, Brawley, & Jemal, 2011).
Many cancers have been associated with activities, elements in the environment,
medications, and with disease processes. Age increases the likelihood of developing
some types of cancer because of the longer exposure to potential carcinogens in the
environment, foods, and other factors (Extermann, 2000). The risk of developing certain
cancers in patients with rheumatic disease varies and has been found to have a higher
prevalence depending upon the rheumatic disease (see Table 3). Several drugs and
classes of drugs, including immunosuppressive agents, have been associated with cancer
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development (Extermann, 2000). (Drugs used to treat autoimmune diseases will be
discussed in depth later in this paper.)
Table 3
Rheumatic Diseases and Associated Malignancies
Rheumatic Disease

Rheumatoid
Arthritis
Primary Sjögren’s
Disease
Primary
Scleroderma

Organs Primarily
Impacted by the
Rheumatic Disease
Joints

Most Common
Types of Cancer

Cancer Origin

Lymphomas

Blood & lymph

Mucous membranes

Lymphomas

Blood & lymph

Integumentary

Alveolar cell
carcinoma
Non-melanoma skin
cancer
Adenocarcinoma of
the esophagus
Lymphomas
Hematological
cancers
Gastrointestinal
cancers

Respiratory

SLE
Celiac Disease

Various
GI

Inflammatory
Bowel Disease

GI

Integumentary
Gastrointestinal (GI)
Blood & lymph

Turesson and Matteson (2013) noted that persons with rheumatoid arthritis have
been found to have an increased risk of developing lymphomas, which are cancers that
originate in the immune system and more specifically the lymphatic system. This finding
is significant because several research studies have found HL and NHL to be elevated in
patients with SLE. Both of the cancers originate in the immune system and more
specifically in the lymphatic system.
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Malignant lymphomas are classified according to the cell of origin and the
biological understanding of the cell type; they have been indexed by the World Health
Organization (WHO) (Word & Matasar, 2012). The malignant lymphomas are
heterogeneous and originate from either B cells or T cells (Word & Matasar, 2012). B
lymphocytes (B cells) fight against viruses and bacteria by producing proteins called
antibodies, which attach to the germ so that other cells in the immune system know that
they need to destroy them (American College of Rheumatology [ACR], 2013). T cells
either destroy the marked germs, or they release other substances, which will digest the
marked germs (ACR, 2013). The WHO has classified more than 50 types of lymphomas.
However, I focused primarily on two types: non-Hodgkin’s (NHL) and Hodgkin’s
lymphomas (HL). In 2011, approximately 66, 360 cases of NHL cases and approximately
8,830 cases of HL cases were diagnosed (Siegel et al., 2011). Previous studies have
shown that NHLs and HLs have both been elevated in patients with SLE.
HL results from the malignant transformation of a B cell at either the postgerminal or post-germinal center stage of development (Word & Matasar, 2012). Of the
8,830 cases of HL diagnosed in 2011, approximately 1,300 resulted in death (Siegel et
al., 2011). Diagnosis is more prominent in patients aged 20 to 29 years or greater than
age 50 years; in addition, HL has a higher incidence in males than in females (Word &
Matasar, 2012). In approximately 40% of HL cases, Epstein-Barr virus is detectable, and
it is thought to be directly involved in the transformation to cancerous cells (Word &
Matasar, 2012). This association of a virus in the transformation to cancerous cells has

28
also been a possible precursor in the transformation of the body producing antibodies
against itself as in autoimmune diseases.
NHL also starts in the lymphocytes. There are several subtypes of NHLs but I
primarily focused on the diffuse large B cell lymphoma (DLBCL). Mucosa-associated
lymphoid tissue (MALT) type NHLs are often found following an autoimmune or
chronic infectious process (Word & Matasar, 2012). The pathophysiology involves
chronic stimulation of B lymphocytes by a persistent infection or autoimmune
phenomenon that results in the cells cloning themselves (Word & Matasar, 2012). The
DLBCL may occur as a transformation of a previously existing slow lymphoma that may
or may not have been previously diagnosed (Word & Matasar, 2012). A weakened
immune system and certain types of infections contribute to the development of NHLs.
Certain infections have also been attributed to the production of autoantibodies, which act
against the body, as in autoimmune diseases.
A greater incidence of lymphoproliferative cancers in autoimmune diseases
should be expected because the chronic activation of B cells and T cells that occur in
autoimmune diseases could serve as a catalyst to cancer development (Turesson &
Matteson, 2013). Ragnarsson, Grondal, and Steinsson (2003) determined that patients
with SLE are at increased risk for cancer development; surprisingly, prostate cancer was
found to be increased in men with SLE. There was speculation that the increased prostate
cancer rate could be possibly attributed to etiological mechanisms in males with an
autoimmune disease, such as increased levels of antibodies against estrogen receptors,
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which result in a decrease in the protective effect of estrogen for prostate cancer
(Ragnarsson et al., 2003).
Common Links between Cancers and Systemic Lupus Erythematosus
Researchers have proposed several risk factors for the development of cancer
among persons with SLE that would support an increased risk of cancer in this
population, including the use of immunosuppressive agents, which increases the
development of malignancies (Bernatsky et al., 2006). Other risk factors that have been
suggested, although not fully explored, include genetic predisposition such as the
presence of anti-phospholipid antibodies, which are frequently present in persons with
both SLE and cancer; lifestyle-related risk factors such as smoking; and abnormalities in
cell death regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2009).
Both SLE and cancers are the result of cells in the body behaving in a manner that
was not intended. These abnormal cell activities have some commonality in that (a) they
have patterns of dysregulation that are similar such as autoantibodies in the blood; (b)
they have bidirectional linkages as evidenced by clinical manifestations; and (c)
immunosuppressive drugs used to treat these diseases can have an impact in cancer
development (Achenza & Selmi, 2012). All cancers originate in cells of the body, which
are the basic units of life (NCI, 2014). The fact that both cancers and autoimmune
diseases originate at the cellular level is a primary link that may be instrumental in
understanding whether the two disorders have an association with each other. The
overstimulation of B cells along with a defective immune system contributes to the
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greater propensity for lymphomas to be found in persons with autoimmune diseases
(Cristaldi et al., 2011).
Abu-Shakra, Ehrenfeld, and Shoenfeld (2002) proposed that both autoimmune
diseases and cancers have common etiologic agents such as environmental factors, the
use of immunosuppressive agents, genetic factors that render them susceptible, and
disturbances in the immune system. In the case of cancer and autoimmune diseases, it is
difficult to determine which began first and whether the advent of one created a suitable
environment for the other to begin. In addition, whether the use of treatment drugs caused
the development of either lymphoma or an autoimmune disease is also questionable.
These are the major issues faced when assessing the association of cancer in autoimmune
diseases. Because of the heterogeneity of both cancers and autoimmune disorders, a
causal relationship can be difficult to determine with certainty. Rosenquist (2008) found
associations between inflammation, infectious agents, and certain lymphomas. The
genetic make-up of individuals plays a role in the development of SLE and cancer as
does the diet; the air quality; exposure to drugs, other than ones used for treatment for
one of the disorders; and habits, such as smoking and tanning, which significantly impact
the association. These are just a few of the numerous factors that may affect the
association of cancer and SLE. These factors can cause a great impact on an association
between cancer and autoimmune diseases.
Bei et al. (2009) studied the interaction between autoantibodies in cancer patients
versus autoimmune patients. The authors found an overlap of antibodies that must be
considered because they can change the properties of each other and can also affect the
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growth and progression of each disease. Most studies conducted to date have been
relatively small in size and unable adequately to examine the development and exposures
of cancers that are not common. Outcomes from this study revealed that there is an
association of cancer development in patients with SLE. More specific association of
cervical cancers was also assessed in this study. The study outcomes could promote
positive social change by reinforcing current recommendations for cancer screenings
particularly in persons with SLE. Stronger adherence to cancer screening
recommendations could enhance the ability to detect a cancer early enough so that
treatment can be implemented that may result in a higher likelihood to effectively
eradicate the cancer and decrease mortality due to cancer in persons with SLE. Results
from this study may also equip persons with SLE with scientifically-based knowledge
that will enable them to make decisions regarding their care with a clearer understanding
of the cancer risks inherent to persons with SLE, particularly when factored with their
knowledge of their personal familial risks for cancer development.
Incidence of Cancer in Autoimmune Diseases
Various types of cancer, including but not limited to cervical cancer and lung
cancer, are thought to be increased in patients with SLE when compared to persons
without SLE (Bernatsky et al., 2005; Kiss et al., 2010; Parikh-Patel et al., 2008).
Researchers have proposed several risk factors for the development of cancer among
persons with SLE that would support an increased risk of cancer in this population,
including the use of immunosuppressive agents, which increase the development of
malignancies (Bernatsky et al., 2006). Other risk factors that have been suggested,
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although not fully explored, include genetic predisposition such as the presence of antiphospholipid antibodies, which are frequently present in persons with both SLE and
cancer, lifestyle-related risk factors such as smoking, and abnormalities in cell death
regulation (Kiss et al., 2010; Schultz & Harrington, 2003; Tincani et al., 2010).
Whether SLE is associated with a higher rate of cancer is uncertain (Bernatsky et
al., 2005). Previous research in this area has been based upon small study samples,
cohorts that were not closed, which could increase the number of patients lost to followup; moreover, the studies have lacked definitive diagnosis dates for SLE in the
participants (Bernatsky et al., 2005; Parikh-Patel et al., 2008). As a result, previous
studies were generally underpowered to determine conclusively whether a relationship
exists between SLE and cancer (Bernatsky et al., 2005). The smaller sample sizes did not
permit an examination of cancers that are diagnosed at a lower incidence, which is
important because of the various associated risk factors, etiology, and pathophysiology of
cancers that occur less frequently.
Cancer Development and Systemic Lupus Erythematosus Disease
Studies completed to date have shown variable relationships between cancer
developments in persons with SLE. The positive associations between hematologic
cancers and several autoimmune diseases have been repeatedly demonstrated in several
studies to date. Bernatsky et al. (2008) studied immunosuppressive therapy in SLE
patients and found that immunosuppressive therapy may not be the principle driving
factor for overall cancer risk, but may contribute to an increased risk of hematological
cancers and is likely a plethora of causes that result in cancer development in SLE
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patients. Broadbent (2009), in an examination of disease causation models, confirmed
that a thorough understanding of the effects of various factors that contribute to a disease
is necessary to measure an association of the variable to disease development. Kiss et al.
(2010) identified several malignancies such as NHL, cervical cancer, and bronchial
carcinomas, which are found in patients with SLE, are increased, and SLE patients have
an increased incidence and risk of cancer development with the highest risk occurring in
the first year of disease diagnosis. Nived et al. (2001) followed SLE patients to determine
the rate of new malignancies following initial SLE diagnosis. Parikh-Patel et al. (2008)
determined that patients with SLE have an increased risk of developing hematologic,
kidney, and thyroid cancers. Hildalgo-Conde et al. (2013) actually suggested the
incidence of cancer was four times greater than expected in a cohort study of Spanish
patients.
Systemic Lupus Erythematosus Treatment Drugs and Cancer Development
Over the years, many drug classes have been found to be carcinogenic (Azab et
al., 2008). Unlike many autoimmune diseases, SLE has only recently had a drug
approved for the treatment of the disease. Until belimumab (Benlysta™) was approved
for the treatment of SLE, other drugs were used as off-label treatments. The standard of
care for SLE includes anti-inflammatory drugs, corticosteroids, antimalarial drugs,
immunosuppressive drugs, and anticoagulants (Azab et al., 2008). Anti-inflammatory
drugs, such as aspirin, acetaminophen, and non-steroidal anti-inflammatory drugs
(NSAIDs) such as ibuprofen, are used to decrease inflammation. Corticosteroids are used
to decrease swelling, warmth, tenderness, and pain associated with inflammation.
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Antimalarial drugs are used for skin rashes. Immunosuppressive drugs are used to control
inflammation when corticosteroid drugs have not effectively controlled the inflammation.
Anticoagulants are used in SLE patients to prevent blood clots that can result from
decreased mobility in people with SLE.
Bernatsky et al. (2008) proposed that immunosuppressive medications used to
treat SLE may not be the main factor for overall cancer risk in SLE patients.
Immunosuppressive medications may contribute to an increased risk of developing
hematologic cancers, and suggests that future studies should evaluate other factors that
increase the risk for malignancy in patients with SLE. Chang et al. (2005) found that use
of NSAIDs to treat inflammation increased the risk of NHL. A study by Engels et al.
(2005) found Sjögren’s syndrome to have the strongest association in a study to assess
immune-related conditions and immune-modulating medications as risk factors for NHL.
The theoretical framework for this study was the disease causation theory. The
basic component of the disease causation theory is that diseases are caused by multiple
factors and cannot be independently attributed to a sole causative agent (Broadbent,
2009). The multifactor framework was most useful because of the use of immunecompromising treatments for SLE treatment and disease activity in SLE, both of which
could possibly contribute to increased risk of cancer development. Determining the cause
for CNCDs is challenging because they involve multiple factors that interact and result in
the disease state. This study involved two CNCDs, SLE, and cancers. Complexities of
these two CNCDs required the use of a multifactorial causation theory.

35
Summary and Conclusions
Studies completed to date have shown variable relationships between cancer
developments in persons with SLE. The smaller sample sizes of previous studies have not
allowed an examination of cancers that are diagnosed at a lower incidence, which is
important because of the various associated risk factors, etiology, and pathophysiology of
cancers that occur less frequently. There is a gap in the current literature available on the
association of cancer development in SLE patients, and it is not definitively know if there
is an increased incidence of cancer development in SLE patients.
In this study, careful consideration was given to the multiple factors that have an
interaction in SLE and in cancer. A large, population-based database was used to assess
the relationship between SLE and cancer in a large population. The larger sample size in
this study allowed cancers that occur less frequently to be examined. Finally, this study
examined the incidence rates of various cancer types found in patients with SLE. The
design of the study and the methods used to assess the findings were dynamic enough to
allow for a detailed analysis that can be easily understood. The next chapter will provide
details of the research design and methodology that was used in this study. A discussion
of threats to validity will also be included in the upcoming chapter.
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Chapter 3: Research Method
Introduction
In Chapter 2, I presented the results of several research studies on the possible
risk factors for the development of cancer among persons with SLE. They included the
use of immunosuppressive agents, genetic predisposition (presence of antiphospholipid
antibodies), lifestyle-related risk factors such as smoking, and abnormalities in cell death
regulation (Bernatsky et al., 2006; Kiss et al., 2010; Schultz & Harrington, 2003; Tincani
et al., 2010). However, whether SLE is associated with a higher rate of cancer is
uncertain. A notable limitation with the existing research in this area (small study
samples, low retention rates, and a lack of a definitive and consistent diagnosis of SLE in
the study participants) renders uncertainty about the ability to apply rates found to the
general population (Bernatsky et al., 2005; Parikh-Patel et al., 2008). Moreover, the small
sample sizes of several of the studies presented in the previous chapter prohibit an
examination of cancers that are diagnosed less frequently. Less frequently diagnosed
cancers are important because of the various associated risk factors, etiology, and
pathophysiology of tumors that may occur less frequently.
This study was designed to address the limitations of previous research. I used a
population-based database (CPRD) with a large sample size, which permitted an
examination of cancers that occur at a lower incidence. Follow-up was not problematic
because all data had already been collected and archived in the respective database. SLE
was defined as any patient who had been diagnosed with SLE as per the American
College of Rheumatology criteria for diagnosis of SLE.
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In this chapter, the study design will be described along with the justification for
the use of the analytical approach including its advantages over other models and
limitations. A description of the target population will also be presented. The calculation
of the minimum sample size needed to show an adequate statistical power to detect a
treatment effect will be provided, along with the parameters and assumptions used to
perform this computation. Finally, the procedure for gaining access to data archived in
the CPRD will be described along with a description of anticipated threats to validity and
potential ethical issues that were encountered during the study.
Research Design and Rationale
A matched, retrospective, cohort study among SLE and non-SLE patients
identified in the CPRD was conducted to assess the association of cancer development in
patients with SLE. SLE patients, including both prevalent and incident cases, were used
in the study. Incident cases were defined as those with the first diagnosis of SLE after the
last date of current registration (CRD) and the practice up-to-standard (UTS) date plus 12
months. The CRD was the date that the patient’s information was entered into the CPRD;
whereas, the practice UTS date was the date that the CPRD staff confirmed that the data
met their internal quality standards. Prevalent cases were defined as those that had the
first SLE diagnosis prior to the later of the CRD date and the UTS date plus 12 months.
The index date for incident cases was the date of SLE diagnosis. The index date for the
prevalent cases was the later of the CRD date and UTS date plus 12 months. The
comparison group was a non-SLE cohort selected from CPRD. Non-SLE patients must
not have had a SLE diagnosis at any time during the period considered for the SLE
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cohort. This exclusion criterion prevented patients who experienced drug-induced lupus
erythematosus (DILE) from entering the study. DILE can result after taking certain drugs
and usually resolves on its own. Because DILE has a different pathophysiology than
SLE, it was not included in this study.
Randomization that occurs in a randomized controlled trial (RCT) theoretically
ensures a balance of measured and unmeasured covariates amongst the experimental and
the control groups (Austin, 2011). However, in an observational study, the patients are
assigned to a group, but the groups will differ in systematic ways. This method of group
assignment did not take into consideration the fact that patients in either group may have
had concurrent diseases, may have been undergoing treatments, and may have possessed
other characteristics that could interfere with an equitable evaluation of the outcome
(Sugihara, 2010). Group assignment without a method to control for confounding
characteristics introduces selection bias for the study because the study results were not
generalizable because of the numerous confounding variables for both cancer and SLE.
Studies of association of cancer development in patients with SLE have not used a
propensity score methodology until this study. The study design allows the cohorts to be
balanced better than previous studies that have assessed cancer development in patients
with SLE. Sugihara (2010) recommended the use of propensity score methodology in
observational studies in which multiple confounding characteristics are present in the
patients. This method helps to balance the differences between comparison groups. The
propensity score is the predicted probability given a determined set of measured
covariates (Rassen, Glynn, Rothman, Setoguchi, & Schneeweiss, 2012). The propensity
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score allows an observational (nonrandomized) study to be designed and analyzed, so
that it mimics many of the characteristics of an RCT (Austin, 2011). This method is
based upon the creation of a similar distribution of observed baseline covariates between
the two groups, and it was used in this study to help to balance the measured differences
between the comparison groups.
The propensity score analysis in this study began by identifying risk factors for
SLE. A logistic regression model was used to determine the risk of developing SLE. The
predicted probability of developing SLE p(SLE) was going to be calculated by the
regression of the covariates on a dichotomous variable for whether a patient has SLE.
This calculation would have produced a probability of SLE for each woman in the cohort.
Patients with and without SLE would have be matched based on the p(SLE) (Caliendo &
Kopeinig, 2005). This matching could only occur within the area of common support,
which is the range of p(SLE) that is common to both the SLE and non-SLE women, so it
would exclude women with very high and low probability of having SLE.
Once the risk factors that contribute to the development of SLE were determined,
a test to check if the matching procedure balanced the distribution of the relevant
variables in the control and treatment groups would have been performed (Caliendo &
Kopeinig, 2005). A D-statistic test would have been used to determine if the SLE and
non-SLE patients had significant differences. The purpose of this step would have been to
balance the cohorts, somewhat analogous to randomization in an RCT (Caliendo &
Kopeinig, 2005).
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After determining the two cohorts, the risk factors for cancer development were
used to determine the predicted probability of patients in the SLE cohort and in the nonSLE cohort to develop the outcome of cancer p(CA). This was going to be done by again
using a logistic regression model. Next, the relative risk (RR) would have been
determined using proportional hazards regression (Cox, 1972). The exponentiated
coefficients on each covariate are an odds ratio of the odds of cancer. A survival analysis
would have been done using the proportional hazard regression model.
The use of a high dimensional propensity model allowed the computer program to
search the database and determine common variables in patients with SLE. In this case, I
used concurrent diagnoses and medications. Austin (2011) described propensity scores as
using baseline characteristics to assign patients to a treatment group. In this study, the
average treatment effect (ATE) was the outcome framework that was used. The ATE is
the average effect at the population level when the whole group is moved from untreated
to treated (Austin, 2011). The other framework that could have been used was the
average treatment effect for the treated (ATT). The ATT is the average effect of
treatment only for patients who actually received treatment (Austin, 2011). The ATE
framework was more advantageous in this study because it was more important to
estimate the effect of cancer development in persons with SLE versus in patients without
SLE (Austin, 2011).
Because an observational database was used, the comparative effectiveness of
covariates was estimated by using the propensity score. This computer-assigned
propensity score was used to compare individuals with similarly estimated scores by
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either matching or stratification (Curtis, Hammill, Eisenstein, Kramer, & Anstrom, 2007).
Matching by propensity scores would have matched patients in one treatment group
directly to a patient in another treatment group solely based on the propensity score. To
use stratification, the difference in the ATE of the two groups and then the average effect
would have been calculated within each stratum (Curtis et al., 2007). The number of
potential patients for inclusion in the study and the use of stratification would have
increased the probability similarities in the two comparison groups; however, it may have
been difficult to distinguish the patients from one another (Curtis et al., 2007). Inverse
Propensity Weighting (IPW) would employ less distributional assumptions about the
data, prevent additional confounding, could incorporate time dependent covariates, and
could also manage censored data (Curtis et al., 2007).
In addition to using propensity scoring to match patients for participation in an
observational study, the treatment effect could also have been assessed by evaluating the
multiple variables identified (Heinze & Jüni, 2011). Use of propensity scoring for
observed covariates for cohort selection in this study would have assisted in decreasing
the many sources of bias, which result from SLE. Both of these diseases have suggestive
causes and overlapping factors that may predispose a person to the development of either
or both diseases. In this study, matching of SLE patients to non-SLE patients using
conventional randomization measures would have introduced bias into the analyses
because of the numerous risk factors associated with the outcome of cancer development
(Heinze & Jüni, 2011).
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After matching the patients by propensity scores, they were going to be linked to
the HES database for data on some covariates for reasons described later in the archival
data section. The cohort design was most suitable for this study to take advantage of all
available data in the secondary data source CPRD. The cohort design allowed for a
thorough examination of those persons who developed cancer (Song & Chung, 2010).
The longitudinal data contained in CPRD was also used in the cohort design as opposed
to a case control design.
Probability of Systemic Lupus Erythematosus
The primary exposure was SLE, and study patients were designated as SLE or
non-SLE. To calculate the probability of being in the SLE group, I considered the risk
factors for disease in the propensity score approaches. SLE is most prevalent in people of
color (e.g.., African, Asian, Indian, or Hispanic) (CDC, 2014). The onset of SLE usually
occurs between the ages of 16 to 44 years (CDC, 2014). Several exogenous and
endogenous risk factors contribute to the development of SLE. In a case control study
conducted in Sweden to explore risk factors associated with the development of SLE, a
history of hypertension had an odds ratio (OR) of 3.7 (1.4-9.8), history of a reaction to
the sun had an OR of 2.3 (1.1-4.8), history of a drug allergy had an OR of 3.6 (1.4-9.5),
and a family history of SLE had an OR of 6.8 (1.4-32) (Bengtsson, Rylander, Hagmar,
Nived, & Sturfelt, 2002). The presence of these risk factors independently may not result
in the development of SLE, but a combination of these factors, along with other factors,
may increase the chances of developing SLE. The high OR for a family history of an
autoimmune disease aligns with the known genetic predisposition that is associated with
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many autoimmune diseases. Cooper, Dooley, Treadwell, St. Clair, and Gilkeson (2002)
had similar findings in The Carolina Lupus Study, which was conducted in several
counties in North and South Carolina. SLE risk factors that were to be used to match the
SLE and non-SLE cohorts are listed in Table 4.
Table 4
SLE Risk Factors
Risk Factor

Definition

How Measured

Year of Birth
(proxy for age)
Race

Year of birth

Continuous

Race or ethnicity
reported by the patient

All

Hypertension

Diagnosis of
hypertension at any
time
History of skin
reactions
Documentation of
self-reported family
history of any
autoimmune disease
Diagnosis of a history
of an allergy to an
antibiotic
Self-report or
diagnosis of shingles
or cold sores

African/Black=0
Hispanic=1
Asian=2
Indian=3
Yes or No

Yes or No

All

Yes or No

All

Yes or No

All

Yes or No

All

Ultraviolet Skin
Reactions
Family History of SLE or
Other Autoimmune
Diseases
History of Allergy to
Antibiotics
History of Shingles or
Cold Sores

StudyRelevant
Associated
SLE
All

All

The original plan was to use a logistic regression model to determine the risk of
developing SLE. The predicted probability of developing SLE p(SLE) was going to be
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determined by matching the covariates between the SLE and non-SLE women in CPRD.
This calculation would have been used to identify the cohorts of SLE and non-SLE
patients by matching the risk factors for SLE in both populations. The matched patients
who fall within the area of common support would have made up the SLE and non-SLE
cohorts in the study.
Probability of Cancer
The outcomes for this study included incident cancer (all types) and cervical
cancer in particular. Cancer diagnoses were identified in the CPRD and HES. Incident
cases included cases in which cancer was first diagnosed after the index date in people
with at least 12 months of registration in the CPRD. The first diagnosis of each cancer
type was used in instances where a person had multiple cancer diagnoses at different
times.
Numerous risk factors may increase the chance of developing cancers (WHO,
2014). All of the cancer causing risk factors cannot be addressed in one study because of
the limitations using the existing data in the CPRD and HES database. In this study,
therefore, I analyzed some of the most common risk factors that are routinely included in
the medical history of a database, such as the CPRD. The cancer risk factors in this study
were to include age, tobacco use, human papillomavirus (HPV) infection, Epstein-Barr
virus (EPV) infection, overweight, pregnancy history, and oral contraceptive (OC) use.
Age (greater than 65 years) is a risk factor for most types of cancers (CDC, 2014).
As a person ages, he or she is exposed to a multitude of elements, including
environmental and lifestyle factors that are associated with an increased risk of general
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cancer development (CDC, 2014). The CDC determined that environmental exposures,
such as air pollution, secondhand tobacco smoke, asbestos, drinking water containing
large amounts of arsenic, and pesticides, are linked to some cancers such as lung, skin,
and bladder. Lifestyle elements, such as cigarette smoking, tobacco use, infections,
radiation, immunosuppressive medicines, diet, alcohol, physical activity, and obesity, are
either known to increase cancer risk or may affect the likelihood of cancer (CDC, 2014).
Exposure to tobacco, such as smoking, snuff, and chewing tobacco, is the most
preventable risk factor for lung cancer, and it contributes to cancers such as mouth, nose,
throat, larynx, esophagus, liver, bladder, kidney, pancreas, colon, rectum, cervix,
stomach, blood, and bone marrow (CDC, 2014). Smoking renders a person exposed to
many cancer-causing chemicals that affect multiple body organs when the chemicals are
carried via the blood system to the organs. The chemicals act to damage the DNA of cells
and may contribute to the development of multiple cancers (American Cancer Society
[ACS], 2014). A history of tobacco use was a cancer risk factor in this study and was
measured as either yes or no.
A history of infection with certain viruses and some bacteria can increase the risk
of developing cancer (CDC, 2014). Infections with certain viruses and bacteria increase
the risk of cancer development because the infection changes the person’s DNA, and
changes the behavior of the cells which may cause them to replicate at a rate greater than
necessary, which is cancer (Cancer Research United Kingdom, 2014). In this study, I
analyzed the impact of EBV and HPV in cancer development of lymphoma and cervical
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cancer respectively. HPV is a routine test that is a part of the Papanicolaou (PAP) test for
females.
A person that is overweight or has a Body Mass Index (BMI), which is a measure
of body fat based upon height and weight, has been attributed as a risk factor of
developing cancer. Being overweight, which can be a result of a poor diet or a lack of
adequate physical activity, increases the risk of cancers such as colon, uterus, prostate,
esophagus, breast, and kidney (CDC, 2014). In addition to increased BMIs and increased
levels of estrogens and insulin, which are also associated with being overweight or obese,
are some of reasons for increased cancer development (Cancer Research United
Kingdom, 2014.
A full-term pregnancy before the age of 17, as compared to a woman who had the
first pregnancy after the age of 25, and women that had more than three pregnancies are
associated with an increase in the risk of cervical cancer development (CDC, 2014).
These two factors increase the risk of cervical cancer development because they increase
the chances of acquiring a HPV infection due to the potential of the woman having
unprotected sex with a greater number of sexual partners (ACS, 2014). The hormonal
changes associated with pregnancy may also contribute to a weakened immune system
and render the woman susceptible to HPV infection (ACS, 2014).
Use of estrogen-progestagen OCs over a 5-year or greater period may increase the
development of cervical cancer (CDC, 2014). A study that analyzed the effect of OC use
with a background of HPV infection showed that the use of an OC for more than 5 years
by women that had a HPV resulted in increased rates of cervical cancer (Smith et al.,
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2003). Although HPV exposure is known to be the most important cause of cervical
cancer, when combined with long-term use of OCs, the relative risk (RR) of cervical
cancer development was increased as duration of use increased (Smith et al., 2003).
Smith et al. studied women with cervical cancer with no history of OC use (RR 1.9-2.2)
compared to women who had used OCs (RR 1.6-3.9) for more than 10 years and found
the incidence of cervical cancer increased with longer use of OCs.
Other risk factors could be included but would require a specially designed data
collection tool. These other factors would include sunlight exposure; ionizing radiation
exposure; exposure to chemicals such as asbestos, benzene, and cadmium; family history
of cancer; alcohol use; and diet and physical activity. Because the CPRD does not contain
the detailed risk factors mentioned, it was not possible to assess these cancer risk factors
in this study. However, the cancer-associated risk factors that I had planned to be
included in this study are listed in Table 5.
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Table 5
Cancer Risk Factors
Risk Factor

Definition

Age
(independent)

Number of years the
patient has been alive at
the time of CPRD entry
Use of any tobacco
product such as cigarettes,
cigars, pipes, snuff, or
chewing tobacco
Positive HPV infection at
any time
Positive EBV infection at
any time
Having a body mass index
(BMI) greater than 25
Age of 1st pregnancy and
number of pregnancies
Use of an OC

Tobacco Use

HPV Infection
EBV Infection
Overweight
Pregnancy History
Contraceptive
History

How
Measured
Numerical

Study-Relevant
Associated Cancer
All

Yes or No

Cervical
All Cancers

Yes or No

Cervical

Yes or No

Cervical

Yes or No

Cancer

Categorical

Cervical

Yes or No

Cervical

Propensity scores were initially going to be used for matching, which would have
balanced the differences between the patients included in the study. Propensity scoring
was going to be used to evaluate the multiple variables that could be used to match the
comparison groups (Heinze & Jüni, 2011). The decrease in the many sources of bias that
result as related to SLE was to be controlled with the use of propensity scores.
Treatment effect was going to be assessed by evaluating the multiple cancerrelated risk factors that were identified based on the literature review (Heinze & Jüni,
2011). Cancer and specifically cervical cancer have numerous strongly suggestive causes
and overlapping factors that may predispose a person to development of either or both
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diseases. None of the previous researchers performed an analysis of the outcome risk
factors and incorporated this information into the overall measure of association.
The Database
Resource constraints encountered with the design choice include the cost to link
data from the CPRD to other data sources such as the UK cancer registry. This limitation
resulted in the reliance on HES data rather than data from the cancer registry. CPRD
(2013) estimated that a link between the CPRD and the UK cancer registry would cost
approximately $16,000. The cost would pay the CPRD staff to link data in the CPRD
with data in the cancer registry. Limited funding did not allow me to establish the linkage
to the UK cancer registry for this study because I was not able to secure the funds from
my employer, nor was I able to personally support the costs to link the CPRD with the
UK cancer registry. Because of this resource constraint, I decided to rely on data that
could be found in the CPRD and HES.
Time constraints consistent with the design choice included working closely with
programmers to obtain the proper data from the CPRD. Variables were defined as
concepts, so that the needed variables could be retrieved from the CPRD. Once obtained,
additional time was invested to review the data to confirm the inclusion and exclusion of
variables that were not primary malignancies. In the initial plan, a method to match the
patients in the other databases would have been implemented once the cohorts were
selected. The matching would have taken a significant amount of time to ensure that the
cohorts were matched appropriately. Once matched, several analyses and testing of the
data would need to have been completed. There would have been a significant amount of
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time required because of the design choice: however, the time constraint was not as high
as it would have been if raw data had to be collected and assimilated, as in a primary data
collection study. I recognized there were time constraints associated with this study, and
allowances had to be factored in to allow the necessary time needed to complete this
study successfully.
Frankfort-Nachmias and Nachmias (2008) explained that the non-interventional
observational study design is made up of two groups for comparison: an exposed group
and a control group. These two equal groups are either exposed to the independent
variable (i.e., active disease) or not exposed to it (i.e., no active disease). In this study, the
comparison groups included patients with SLE and non-SLE patients. The study observed
whether the presence of SLE had an influence on cancer development (dependent
variable). Equitable selection of the cohorts decreased bias, which would compromise
associations detected in the study. Exposure to the treatment allowed for the evaluation of
the treatment and an assessment to be made of how the treatment would affect the general
population.
A quantitative study design was used in this study. A propensity score matched
retrospective cohort study between a cohort of SLE and non-SLE patients identified in
the CPRD database was initially planned for this study. The study assessed the
association of cancer development in patients with SLE. SLE patients consisted of either
prevalent or incident cases. Non-SLE patients were to be matched with SLE patients
using the p(SLE). The patients were then to be linked to the UK Death Registry for death
due to cancer. Data were linked to the HES database for additional information on the
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covariates. The cohort design was most suitable because it allowed multiple outcomes to
be examined, enabled causality to be assessed, was good for investigating rare exposures,
and this design would also allow calculation of disease rates in the exposed and
unexposed patients (Song & Chung, 2010).
This study assessed the association of cancer in patients with SLE. Because both
SLE and cancer have many proposed causes, the disease causation theory served as
framework for this study. The disease causation theory suggests that diseases have many
causes that cannot be independently attributed to a sole causative agent (Broadbent,
2009). This multifactorial framework served as the basis to assess the identified cancerrelated risk factors and cancer development in patients with SLE. This framework also
helped to evaluate the development of particular types of cancers, such as cervical cancer
in patients with SLE.
Methodology
Population
The source population was obtained from the CPRD. The study population
included all females with SLE and with no SLE. All female SLE patients with a diagnosis
of SLE included in the area of common support in CPRD (i.e., prevalent and incident
cases) were included. Drug-induced lupus cases were excluded because they are of a
different etiology than SLE. Patients with cutaneous lupus were excluded because they
do not follow the same pathophysiology as SLE. The only restriction on age was that they
be 18 years old. Patients were followed for up to 10 years. Because patients with a SLE
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diagnosis prior to their registration in the CPRD, prior to their current registration date
(CRD), were likely to get a cancer diagnosis entered within the first few months after
registration, which results in the incidence of diseases being overestimated during this
period (Lewis, Bilker, Weinstein, & Stron, 2005). Therefore, incident cases were defined
as those with the first diagnosis of SLE after the latest of the CRD and the practice up-tostandard (UTS) date plus 12 months. Prevalent cases were defined as those that had the
first SLE diagnosis prior to the later of the CRD date and the UTS date plus 12 months.
The index date for incident cases was the date of SLE diagnosis. The index date for the
prevalent case was the later of the CRD date and UTS date plus 12 months. The
comparison group was the non-SLE cohort selected from CPRD. Patients must not have
had an SLE diagnosis at any time during the period considered for the SLE cohort. NonSLE patients were to be matched individually to SLE patients based upon the propensity
weights.
Sampling and Sampling Procedures
All female SLE and non-SLE patients in the CPRD who fell within the area of
common support were to be included in the study. An initial assessment of the CPRD
database revealed that approximately 4,000 female patients in CPRD had SLE (both new
and prevalent cases) and of those 4,000, roughly 2,000 could be linked to other registries.
The necessary sample size was calculated using clincalc.com, which was provided by
Clincalc, LLC. To determine the sample size needed adequately to power the study, the
overall incidence of cancer in females in the United Kingdom used was 266/100,000 or
0.27% (Cancer Research United Kingdom, 2014). The incidence of cancer anticipated in
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SLE women in CPRD used was 18.88/1000 or 1.89% (SAEfetyworks, 2015). The
probability of type-1 error was 0.05 and the power was set at 0.80 with the enrollment
ratio being 1 or equal cohort sizes (see Table 6). Using these numerical settings, it was
calculated that the total study size needed to have sufficient statistical power to detect a
difference (type II error) was 1,276 total with 638 patients assigned to each of the
cohorts, SLE and non-SLE.
Table 6
Parameters Used for Sample Size Calculation
Incidence, group 1(non-SLE)
Incidence, group 2 (SLE)
Alpha
Beta
Power

0.27%
1.89%
0.05
0.2
0.8

Archival Data
The CPRD is funded by the National Health Services (NHS) National Institute for
Health Research (NIHR) and Medicines and Healthcare products Regulatory Agency
(MHRA). CPRD has been used in more than 890 clinical reviews and papers, and the
database is considered the gold standard by many because the high compliance of health
care providers entering the data into the database (Clinical Practice Research Database,
2013). The CPRD is managed by a group that serves the general practitioners who enter
the data into the database, and the managing group serves researchers by anonymizing the
data so that it can be linked to other databases (CPRD, 2013). The CPRD is a combined
effort of the MHRA’s General Practice Research Database (GPRD) and the Department
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of Health’s NIHR Research Capability Program (RCP) into a secure electronic research
database. The NHS assigns a unique patient identifier number that is only used by a
trusted third party for linkage, and it is never released to researchers (CPRD, 2013). This
anonymized identification number ensures that linkages to other database are valid while
maintaining privacy for the patient. Access and use of CPRD data are controlled under
the laws of the United Kingdom and Europe.
Data in the CPRD are available online after completion of a 2-day training
program provided by the CPRD research team. The training provides background
information about CPRD, data fields contained in the database, linkages available, data
entry information that practitioners follow, and services that CPRD can provide. There
are costs for accessing the CPRD data to cover services provided by the CPRD Research
Team. These costs are either paid by individuals, academic institutions, or business
entities. My access to the CPRD was granted by my employer. The information obtained
from this study will be useful as background information for patients with SLE. My
employer conducts research to develop medicines, and findings from this study will be
helpful in decisions related to studies being conducted for drugs that could potentially be
used as a treatment for SLE. The company had already paid for a number of people that
could have access to the CPRD, and I was approved to be one of the persons who could
have access for the company; therefore, I did not have to pay out of my pockets for
access to the CPRD. There are legal agreements that cover all aspects of the use of the
CPRD data and services (CPRD, 2013).
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There are linkages already established with the Office of National Statistics
(ONS), which contains mortality data. These data are available to researchers after a
research project is approved by the Independent Scientific Advisory Committee (ISAC)
for MHRA database research (CPRD, 2013). The ISAC is an appointed expert advisory
body that provides advice on research requests to access CPRD (CPRD, 2013). A request
to ISAC must include the project’s methodology, information on the medical, statistical,
and epidemiological aspects of the proposed study (CPRD, 2013). ISAC can request
additional information needed in making a determination whether the proposed study in
CPRD will be approved or denied. All investigators and collaborators are included in the
application to have the protocol approved by ISAC.
The CPRD is funded by the NHS, NIHR, and the MHRA (CPRD, 2013). The
CPRD services are designed to improve the way NHS clinical data can be linked to
enable many types of research and deliver useful research outputs (CPRD, 2013). NonSLE patients were to be matched with SLE patients on propensity scores. A link to data
in the HES database was made to obtain data on diagnosis of malignancies. The cohort
design was most suitable for this study to take advantage of all available data in CPRD
and HES database. Types and sources of information or data were CPRD provided
demographic and diagnostic data on patients with SLE, and HES provided information
about SLE diagnosis, cancer diagnoses, diagnostic and laboratory information.
Operationalization
HES is a data warehouse that contains details of approximately 125 million
hospital admissions, outpatient appointments, and emergency records each year at
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National Hospital Services hospitals in England (Health & Social Care Information
Center [HSCIC], 2014). Data entered are administrative in that they allow hospitals to be
paid for the care they deliver (HSCIC, 2014). Although administrative in nature, HES can
be used to monitor trends and patterns in hospital activity, to assess efficient delivery of
care, and to inform patient choice (HES, 2014). The HES database was developed in
1987 after a report that collected hospital information was commissioned by the NHS and
published. The 1987 report was the start of a database that contained information
compiled for each hospital admission and used to assess the severity of SLE disease
activity for patients. Data in HES are collected monthly and are accessible via the
Internet.
Data Analysis Plan
Research Questions
RQ1: Is the risk of cancer development increased in SLE patients compared to
non-SLE patients?
Ho1: There is no increased risk of cancer development in SLE patients compared
to non- SLE patients for overall cancer risk and cervical cancer risk.
Ha 1: There is an increased of cancer development in SLE patients compared to
non-SLE patients for overall cancer risk and cervical cancer risk.
Planned Methodology: Conditional Logistic Regression
To measure incidence of cancer, patients were followed from the index date until
the earliest of the first cancer diagnosis, death, loss to follow-up, or end of study. A
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conditional logistic regression model would have allowed an analysis of binary outcome
data with one or more predictors and where observations were not independent, but were
matched (Statsdirect, 2014).
Planned Methodology: Proportional Hazard Regression
A survival analysis was initially planned, using the proportional hazard regression
model with the index date for the SLE cohort being the earliest date indicated in CPRD
presumed as being the onset date. The index date for the non-SLE cohort would be the
date of enrollment in CPRD. The identified risk factors were to be analyzed to determine
their impact on the development of cancer in patients with SLE. The Cox proportional
hazard model (backward method) was initially planned to be used to examine the relative
effect of each covariate on the incidence of cancer. All analyzes would be performed
using Statistical Analysis System (SAS) version 9.2. SAS is software developed at North
Carolina State University in 1976, and the software can be used for advanced analytics,
data management, predictive analysis, and business intelligence (Statistics Solutions,
2014).
The original plan was to have risks for each cancer site to be determined by
measuring the relative risk, which is the ratio of the probability of an event occurring in
the exposed group to the likelihood of the event occurring in the comparison or
unexposed group to the expected number of cancers. A cohort type study allowed
calculation of incidence, which could be used to calculate relative risk by dividing the
cumulative incidence in the exposed by the cumulative incidence in the unexposed. This
measure would allow a comparison of the variables on the risk of cancer development.
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The cohort design best used the benefits of using the longitudinal data contained in
CPRD. All analyzes were performed using SAS version 9.2.
In multivariable analysis, consideration would be given to all cancer and cervical
cancer known to be related to SLE as the outcome. The primary exposure was SLE or
non-SLE. In addition to overall cancer development, a particular association of cervical
cancer was included. Depending on the power, some cancers may need to be grouped
together to increase power. Because I eventually assessed overall cancer and cervical
cancer, it was not necessary to group cancers. Sensitivity analyses using different
definitions for latency were going to be conducted to take latency of cancer into account
(e.g., 1, 2, 3, 5 years). Although the size of the SLE cohort in CPRD is substantially
larger than in many previous studies, an attempt was be made to take latency for cancer
into account: however, this would be dependent upon the effective sample size and
commensurate level of power.
Threats to Validity
The validity of this study depended on the accuracy and reliability of the
information entered into the database. SLE is a difficult diagnosis to make, and there may
be a risk of including non-SLE patients. As mentioned earlier, cases that were diagnosed
within 6 months were to be excluded because both SLE and cancer have similar
symptoms. They were excluded because it was impossible to determine which diagnosis
occurred first. Allowing cases where it is unknown whether the SLE or cancer was
diagnosed first would threaten the validity of the study.
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Ethical Procedures
The IRB review and approval protected the study and the university by
independently reviewing the methodology being used in the study to determine if there
was any potential for harm to anyone participating in the study (Rudestam & Newton,
2007). This study underwent IRB review and was found that it did not pose an ethical
concern because it was a retrospective study using secondary data from CPRD; the IRB
approval number is 06-03-15-0149603. The study retrospectively assessed the association
of cancer development in persons with SLE disease. The patients were linked to the HES
database for additional data on the variables. All data were historical, and all patients
remained anonymized during all reviews. All data will be stored on my computer at home
and at my place of employment for 5 years after the study is complete. I have access to
these data as well as my employer.
This study involved research to obtain information to assess a public health issue,
cancer development in SLE patients. The study did not involve the provision or
withholding of a medical intervention. This retrospective study did not have people
participating in it; therefore, no determination of full disclosure of information to
potential study participant was needed, which is an activity of the IRB.
Summary
It is uncertain if SLE is associated with a higher rate of cancer. Previous research
in this area has been based upon small study samples; cohorts that were not closed, which
could increase the number of patients lost to follow-up; and the studies have lacked
definitive diagnosis dates for SLE in the participants (Bernatsky et al., 2005; Parikh-Patel
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et al., 2008). Previous studies were underpowered; therefore, they did not allow a
conclusive determination to be made about whether a relationship exists between SLE
and cancer (Bernatsky et al., 2005). The smaller sample sizes were not conducive to an
examination of cancers that occur less frequently. The examination of less frequent
cancers is important because of the various associated risk factors, etiology, and
pathophysiology of these cancers.
This study used a large, population-based database to test the relationship between
SLE and cancer in a large population. The larger sample size in this study allowed
examination of cancers that occur at a lower incidence. This study also examined the
incidence rates of various cancer types found in patients with SLE. Non-SLE patients
were initially going to be matched with SLE patients using IPWE. All participants in this
study had to be at least 18 years of age and the study included a period of 10 years up to
2014. The patients were linked to the HES database so that data on other covariates could
be collected. The cohort design allowed me to take advantage of all available data in
CPRD and HES.
All SLE subjects in CPRD were included in the analysis. Overall incidence of
cancer was the main outcome; in addition, the risk of developing cervical cancer was
examined. Cancer diagnoses identified in the CPRD and HES were assessed to obtain
additional information about the covariates. Year of birth, race, hypertension, ultraviolet
skin reactions, family history of SLE or other autoimmune diseases, history of allergy to
antibiotics, and history of shingles or cold sores were the covariates that I initially
planned to analyze. The covariates that were planned to be included to determine the
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probability of cancer were age, tobacco use, HPV infection, EBV infection, overweight,
pregnancy history, and contraceptive history. Data on the covariates were obtained from
the CPRD and HES.
The disease causation theory served as framework for this study. This theory
acknowledges the understanding that SLE and cancer develop because of several factors
together rather than any one single factor leading to the development of either of these
diseases. This framework served to assess the development of specific types of cancers,
such as cervical cancer, in persons with SLE. Statistical analyzes were performed using
SAS.
In the next chapter, a review of the purpose of the study, research questions, and
hypotheses will be presented. A detailed discussion of the descriptive and demographic
characteristics of the cohorts will be given along with a correlation of the sample
population with the population of interest. The results of all analyses performed will be
presented and details of any challenges encountered with the implementation of the
study. Descriptive characteristics and assumptions will be evaluated and all findings will
be reported. Tables and figures will be displayed to illustrate the results as appropriate. A
thorough examination of steps taken to execute the study will be presented along with a
comparison to previous findings from similar research.
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Chapter 4: Results
Introduction
Chronic non-communicable diseases such as SLE account for a significant
number of deaths, which are often a result of the impact of SLE on various organ systems
(Manzi, 2009). The increased control of SLE flares has decreased the devastation on
organ systems in the body and has resulted in decreased deaths due to SLE activity. This
increased control of SLE disease activity has now allowed researchers to study other
areas of concern relative to persons with SLE (Manzi, 2009). The purpose of this study
was to assess the association of cancer in patients with SLE. Because both SLE and
cancer have a plethora of proposed causes, the disease causation theory was most
appropriate to serve as framework for this study. According to the disease causation
theory, diseases have many causes that cannot be independently attributed as a sole
causative agent (Broadbent, 2009). This multifactorial framework served as a basis to
assess the development of cervical cancer in patients with SLE
A high dimensional propensity weighted, retrospective cohort study among SLE
and non-SLE female patients identified in the CPRD database was used to assess the
association of cancer development in patients with SLE. Female SLE patients with
prevalent and/or incident cases were included in the study. Non-SLE patients were
matched with SLE patients in CPRD. The main exposure for this study was SLE
(exposed) and non-SLE (unexposed) study patients, which was designated as SLE or
non-SLE. The outcome was overall incidence of cancer. The first diagnosis of each
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cancer type was used in instances where the person had multiple cancer diagnoses at
different times.
Research Questions and Hypotheses
The research questions and hypotheses for this study were
RQ1: Is the risk of cancer development increased in SLE patients compared to non-SLE
patients?
H01: There is no increased risk of cancer development in SLE patients compared to nonSLE patients for overall cancer risk as compared to non-SLE population and
cervical cancer risk as compared to non-SLE population.
Ha 1: There is an increased risk of cancer development in SLE patients compared to nonSLE patients for overall cancer risk as compared to non-SLE population and
cervical cancer risk as compared to non-SLE population;
In this chapter, the data collection details will be described. The plans for
collecting the data were discussed in Chapter 3, and any deviations from those plans will
be detailed in this chapter along with rationale for the deviation. The demographics of the
patients will be presented, and an analysis of the patients’ proportionality to the larger
population will be discussed. The results of the analyses that justify the covariates that
were used in the model will be provided and discussed. The statistical analyses that were
used to determine and extract the sample populations will be presented along with the
findings from the analyses that were performed. No additional statistical tests emerged
from the analysis of the main hypotheses. Tables and figures will be included in this
chapter to assist in illustrating the results as appropriate. Finally, the answers to the

64
research questions will be summarized, and the prescriptive materials that will be
presented in Chapter 5 will be introduced.
Data Collection
The source population for this study was patients in CPRD. The study population
included females with SLE. An inverse probability of treatment weights (IPTW) was
performed because the estimate of interest was the ATE or the effect that would be seen
if both the SLE and non-SLE cohorts received the same concurrent diagnoses and the
same concomitant medications (Harder, Stuart, & Anthony. 2010). The IPTW allowed all
of the study patients (SLE and non-SLE) to be weighted up to represent the entire study
population (Harder et al., 2010).
All female SLE patients with a diagnosis of SLE (prevalent and incident cases)
and all non-SLE females in the area of common support in CPRD were included in the
study using propensity scores based on SLE risk factors. Patients had to be at least 18
years of age to be included in the study. Through CPRD, patients were followed for up to
15 years. The index date for this study was the date of SLE diagnosis. The comparison
group was the non-SLE cohort selected from CPRD. Patients must not have had an SLE
diagnosis at any time during the period considered to be included in the non-SLE cohort.
In Chapter 3, the data collection plan was developed based upon predefined
covariates. These variables were selected from a review of published literature on risk
factors associated with developing SLE and risk factors associated with the development
of cancer. The predefined risk factors were to be used to first calculate the probability of
developing SLE. Variables such as race, age, history of hypertension, history of a
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reaction to the sun, and a family history of SLE or other autoimmune diseases were to be
used as risk factors to match the SLE and non-SLE cohorts. Database limitations
prevented me from using all of the risk factors. Later I will present the actual risk factors
that were used to match the SLE and non-SLE cohorts.
Once the SLE and non-SLE cohorts were identified, the original plan was to
determine the probability of cancer in both cohorts by using the same process. Risk
factors for cancer development, as identified in literature reviews, were to be used to
match the SLE and non-SLE cohorts. This would create a comparable population by
controlling for prediction of SLE and the covariates that were chosen. Recognizing that
all of the cancer causing risk factors could not be addressed in one study, some of the
most common risk factors associated with developing cancer, such as increased age
(greater than 65 years), tobacco use or exposure, HPV infection, EBV infection, being
overweight, pregnancy history, and OC use, were to be used. Later, I will present the
method actually used to assess cancer in the SLE and non-SLE cohorts.
Upon attempting to use the predefined risk factors to identify the SLE and nonSLE cohorts, I realized that CPRD did not identify race in the database. Age could be
determined, but history of hypertension, history of a reaction to the sun, and a family
history of SLE or other autoimmune diseases were not standard fields in CPRD. The lack
of these data fields led me to re-evaluate the methods for selecting the cohorts for this
study. A high dimensional propensity score model was used instead of the original study
plan, which was to assign a weight to the predefined variables selected based upon the
literature review.
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In the high dimensional propensity model, a computer program was used to assign
weights to variables based upon the analyses of the common variables related to SLE that
were found in the database (Schneeweiss et al., 2009). In this study, I used the most
common diagnoses and most commonly associated prescriptions used by persons with
SLE. The selected covariates included the top 100 diagnoses and prescriptions that were
found most frequently in the database for the SLE population. The covariates (concurrent
diagnoses and concomitant medications) were then assimilated into a propensity score
based confounder adjustment model (Schneeweiss et al., 2009). The diagnoses and
medications were ranked amongst the SLE population in CPRD, and then they were
matched with the non-SLE population in CPRD. The seven steps used to implement the
high-dimensional substitute adjustment in CPRD are shown in Figure 1.
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Specify data dimensions (i.e., diagnoses,
concomitant medications)
Identify empirical candidate covariates
Assess recurrence
Prioritize covariates
Select covariates for adjustment
Estimate exposure propensity score

Estimate an outcome model

Figure 1. Flow chart for a basic high-dimensional propensity score algorithm
Note: (modified from Schneeweiss et al., 2009, Copyright © Lippincott Williams &
Wilkins).

The CPRD is a health care use database, so data collected were not geared toward
assessing clinical disease development and severity, such as the covariates that had been
identified from the literature review. However, the CPRD does contain a large amount of
data that can be used as proxy to describe disease status. In this study, the SLE and nonSLE cohorts were selected by using the concurrent diagnoses that were commonly
diagnosed in patients with SLE, as proxy. After selecting the female patients with SLE in
CPRD, the most common concurrent diagnoses that SLE patients had were selected. The
concurrent diagnoses were used because SLE is usually accompanied by other disorders
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because of the nature of the disease process of SLE and its impact on all systems of the
body.
The top 100 diagnoses that were given to persons with SLE in the CPRD were
selected. The diagnoses that were identified were ranked in the order of how often the
diagnosis occurred in SLE patients. The concurrent diagnoses were described in groups
of similar types of events. Of the 100 top concurrent type of diagnoses reported for
patients with SLE in the CPRD, approximately 26% of the diagnoses were some form of
pain, such as headache, general pain, or specific events of pain of various body areas.
Pain is a common manifestation of SLE because the body produces antibodies against
itself. The next largest group of events was infections and inflammations, which
accounted for 15% of the concurrent diagnoses. Inflammation is usually an indication of
some type of infection. In patients with SLE, inflammation can be a result of the
breakdown of body processes because of SLE, or it could be a result of the enhanced
development of infections because of using corticosteroids and other medications to treat
the symptoms of SLE. The remainder of the concurrent events was found in the category
of respiratory events (9%), rashes or skin disorders (8%), female-specific events (7%),
gastrointestinal events (6%), malaise (5%), urinary events (5%), and cardiac events (3%)
as displayed in Table 7. All of the concurrent diagnoses before the index date were
descriptive of patients with SLE and the pathophysiology of the disease. A random date
was selected among all encounters for the non-SLE population.
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Table 7
Concurrent Diagnoses in SLE Patients
Event Category
Pains/Aches
Infections/Inflammations
Respiratory
Rash/Skin Irritations
Female Events
Gastrointestinal
Malaise/Fatigue
Urinary
Cardiac

26%
15%
9%
8%
7%
6%
5%
5%
3%

The other proxy used to describe the SLE population was medications that the
SLE patients in CPRD were prescribed prior to the index date. The 100 most frequently
prescribed concomitant medications for SLE patients in CPRD were identified. The top
10 frequently prescribed concomitant medications with their drug class in parenthesis
were acetaminophen (pain), amoxicillin (antibiotic), prednisolone (corticosteroid),
codeine (pain), influenza virus vaccine (prophylactic), diclofenac (inflammation),
hydroxychloroquine (antimalarial), ibuprofen (pain/inflammation), hydrocortisone
(corticosteroid), and trimethoprim (an antibiotic) (see Table 8). All of the concomitant
medications identified by the computer search were in alignment with the manifestations
of the SLE disease process. Other concomitant medications identified were medications
used as off-label treatments for symptoms of SLE.
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Table 8
Frequently Prescribed Concomitant Medications in SLE Patients
Rank

Medication

Drug/Indication

1

Acetaminophen

Pain/Inflammation

2

Amoxicillin

Antibiotic

3

Prednisolone

Corticosteroid

4

Codeine

Pain

A medication specifically for the treatment of SLE was not available until 2013
when Benlysta™ was approved to be sold on the market. Up until 2013, medications
prescribed for SLE patients were for palliative treatment of symptoms that the disease
exhibits and not to cure the disease itself. As noted by the 100 most prescribed
medications identified in the CPRD for the high dimensional propensity score modeling,
none of the medications were specifically for the indication of SLE.
Pain and inflammation were the most commonly prescribed medications for
patients with SLE in the CPRD. Pain and inflammation of the joints are common
manifestations of SLE because the body produces antibodies that work against itself.
Medications for pain and inflammation were the most commonly prescribed class of
medication for patients with SLE in CPRD. Corticosteroids were the second most
prevalently prescribed class of medication. Steroids are used to decrease swelling,
warmth, tenderness, and pain that are associated with inflammation. Long-term steroid
use can cause an increased risk of infections because it suppresses the immune system in
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general. This immune system suppression secondary to corticosteroid use is the reason
that antibiotics and anti-infectives are the third most frequently prescribed class of
medication in the SLE population in CPRD.
The Sample
Once the risk factors that contribute to the development of SLE were determined
and the cohorts were identified, an OR estimate was performed to determine if there was
an increased probability of incurring SLE p(SLE) if the patient had been diagnosed with
certain concurrent diseases. Another estimate was run to determine if there was an
increased p(SLE), if the patient had been prescribed particular medications (Le, 2009). Of
the 100 concurrent diagnoses made to SLE patients found in CPRD, the 10 diagnoses
with the highest probability of being made in SLE patients are shown in Table 9. These
findings are consistent with the earlier noted top 10 types of diagnoses found, with the
greatest number of diagnoses being some type of pain, infection, and rash. Because the
population studied was entirely female, female events are noted to be concurrently
diagnosed often in the SLE patients identified in CPRD.

72
Table 9
Diagnoses with the Highest Probability of Being Made in SLE Patients

Diagnosis
Herpes Zoster
Irritable Bowel
Syndrome
Generalized aches
and pains
Cardiac disease
monitoring
Breast lump
symptom
Vomiting
Arthritis
Chest pain
Hemorrhoids
Rash

Point Estimate
27.428
16.431

95% Wald Confidence Limits
Low
High
21.059
35.723
13.63
19.808

1.906

1.6

2.27

1.877

1.541

2.285

1.558

1.283

1.893

1.528
1.51
1.461
1.461
1.455

1.146
1.266
1.312
1.213
1.307

2.036
1.801
1.627
1.76
1.619

Of the 100 concurrent medications prescribed to SLE patients found in CPRD,
the10 medications with the highest probability of being prescribed to SLE patients are
shown in Table 10. An antimalarial (hydroxychloroquine) was the highest prescribed,
followed by a disease modifying antirheumatic drug (azathioprine), then a corticosteroid
(prednisolone), followed by a blood thinner, antihypertensive, a NSAID, a thyroid
hormone, a topical corticosteroid, another DSAID, and an iron supplement. These
medication prescriptions are consistent with the pathophysiology of SLE.

73
Table 10
Medications with the Highest Probability of being Prescribed to SLE Patients

Medication
Hydroxychloroquine
Azathioprine
Prednisolone
Warfarin
Nifedipine
Aspirin
Levothyroxine
Clobestasol
Diclofenac
Ferrous sulfate

Point Estimate
78.859
4.589
3.193
2.847
2.026
1.579
1.443
1.411
1.362
1.303

95% Wald Confidence Limits
Low
High
70.846
87.778
3.885
5.42
2.891
3.525
2.43
3.334
1.735
2.365
1.4
1.781
1.249
1.668
1.202
1.657
1.245
1.489
1.171
1.45

It is important to note that propensity score matching is somewhat different from
matching that occurs in a randomized study; propensity score matching only balances the
observable whereas, in a randomized study both observable and unobservable
distributions are balanced (Lee, 2013). Because the propensity score was used for the
purpose of balancing, it was imperative to run a test to determine whether the propensity
score effectively balanced the covariates used to identify the SLE and non-SLE cohorts.
This balance statistic ensured that the propensity score had the same distribution for both
the SLE group and the non-SLE group. I had to ensure that the treatment medications and
the concurrent diagnoses found in CPRD were distributed in a balanced manner amongst
the SLE and non-SLE cohorts.
An IPTW was performed because the estimate of interest was the ATE or the
effect that would be seen if both the SLE and non-SLE cohorts received the same
concurrent diagnoses and the same concomitant medications (Harder et al., 2010). As
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demonstrated in Figure 2, the IPTW weighting technique assigns each individual patient
a weight or propensity score that is the inverse probability of receiving the treatment that
they actually received; this allows all of the study patients to be weighted up to represent
the entire study population (Harder et al., 2010).

Exposed individuals IPTW = 1 / ρi (a)

Comparison patients IPTW = 1 / (1-ρi)

(a) ρi = propensity score

Figure 2. IPTW weighting technique to assign each individual patient a weight or
propensity score

Heavily weighted covariates would create bias because they would have
significantly more influence in determining the balance of the cohorts. Simply removing
the covariates with the largest weights would create additional bias because the covariates
with the largest weights are the best predictors of the outcome that is being compared.
Therefore, a stabilization technique was applied to decrease the variability of the weights.
The treatment and comparison weights were each independently multiplied by a constant
that was equal to the expected value of being in either group (Harder et al., 2010). Once
the weights were stabilized by the computer program, a technique known as trimming
was used to minimize the influence of any remaining outlying weights.
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Trimming limits the stabilized weight by shortening them to within a specific
range. The goal was to select the trimmed percentile that is most aligned with the
baseline. Figure 3 displays the balance of the diagnoses at baseline, with no trim, at 99%
of SLE trimmed, and at 95% trimmed. A 95% trim was selected because that was most
aligned with the baseline as depicted in Figure 4 with the no trim and 99% trim graphs
removed so that the balance can be seen clearer. The 95% trimmed weights align most
consistently with the baseline weight and therefore, a 95% trimming will be used for the
weights of the diagnoses in CPRD.
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Figure 3. Balance of concurrent diagnoses using IPTW
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Figure 4. Balance of 95% trimmed weights for diagnoses using IPTW
Figure 5 and Figure 6 display the concomitant medications prescribed for SLE
patients in CPRD with the balance of the IPTW weights at baseline, with no trimming, at
99% and at 95% trimmed.
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Figure 5. Balance of concomitant medications using IPTW
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Figure 6. Balance of 95% trimmed weights for concomitant medications using IPTW

Using the concurrent diagnoses and concomitant medications for a highdimensional propensity model rendered an initial SLE population of 3,362 and a nonSLE population of 2,719,084 in CPRD, using IPTW with a 95% trimming to best balance
the weights of the covariates. The IPTW was then applied to the SLE and non-SLE
cohorts that had been identified in CPRD. This application of the IPTW and the trimmed
covariates rendered a SLE cohort of 3,025 and a non-SLE cohort of 180,555 patients.
The sample obtained is an accurate representative to the SLE and non-SLE
populations in the general population. The SLE and non-SLE populations included in the
sample are balanced in the concurrent diagnoses made to each population and they are
balance in the concomitant medications prescribed to them. These balances make both
cohorts equally exposed to covariates that may contribute to the development of SLE.
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The equal exposure to potential covariates will allow a more equitable assessment of
malignancy development amongst the two groups.
To identify primary cancers in CPRD, the Observational Medical Outcome
Partnership (OMOP) vocabulary was used to identify the concept of cancer. The concept
names of neo, mal, and can were used to identify any terms with any of those series of
letters. The initial findings included a great number of events that were (a) benign events
(curable by removal), (b) events that were potential precursors to malignancies, and (c)
not malignancies. Because we only want to include malignancies in this study, and more
specifically, the first malignancy diagnosed, we then added pri to the search. For this
reason, secondary malignancy sites were not included nor were any of the previously
mentioned conditions that were not malignancies. As to be expected, the greatest number
of malignancies included female specific cancers such as breast, uterus, and cervix. The
next largest group of malignancies was in the digestive system. The number of cervical
cancers found in the non-SLE cohort was significantly greater than the number found in
the SLE cohort. A depiction of the malignancies, of which there were at least 10 or
greater events, found in the SLE or non-SLE cohorts in CPRD are listed in Figure 7 and
to indicate that they belong to the same body system in Table 11 and Figure 8.
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Figure 7. Malignancies in SLE and non-SLE cohorts
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Table 11
Malignancies by Body System
SLE (n)
Female Reproductive Cancers
Malignant neoplasm of female breast
Malignant neoplasm of corpus uteri, excluding isthmus
Primary malignant neoplasm of uterine cervix
Malignant neoplasm of endometrium of corpus uteri
Malignant tumor of cervix
Malignant neoplasm of body of uterus
Carcinoma of cervix
Primary malignant neoplasm of vagina
Malignant neoplasm of uterus
Digestive System
Primary malignant neoplasm of colon
Primary malignant neoplasm of sigmoid colon
Malignant tumor of esophagus
Primary malignant neoplasm of rectum
Primary malignant neoplasm of esophagus
Primary malignant neoplasm of stomach
Malignant tumor of intestine
Primary malignant neoplasm of cecum
Primary malignant neoplasm of rectosigmoid junction
Adenocarcinoma of rectum
Malignant tumor of cecum
Malignant tumor of ascending colon
Primary malignant neoplasm of transverse colon
Primary malignant neoplasm of lower third of esophagus
Primary malignant neoplasm of anus
Carcinoma liver and/or biliary system
Primary malignant neoplasm of liver
Integumentary System
Malignant melanoma of skin
Squamous cell carcinoma of skin
Epithelioma basal cell
Urinary System
Primary malignant neoplasm of bladder
Malignant tumor of urinary bladder
Endocrine System
Primary malignant neoplasm of pancreas
Primary malignant neoplasm of ovary
Malignant tumor of ovary
Primary malignant neoplasm of thyroid gland
Primary malignant neoplasm of head of pancreas

Non-SLE (n)

32
5
0
1
1
0
1
0
0

728
78
42
36
36
11
10
10
10

8
2
2
1
2
9
0
2
2
0
1
1
0
0
2
1
1

141
62
57
54
41
33
32
29
28
27
21
17
16
14
12
15
14

7
6
0

113
52
14

2
1

75
50

3
3
2
2
1

57
56
53
37
30
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(table continues)
SLE (n)
Nervous System
Malignant neoplasm of brain
Glioblastoma multiforme
Cardiovascular System
Myelodysplastic syndrome
Multiple myeloma
Lymphatic System
Non-Hodgkin's lymphoma
Hodgkin's disease
Respiratory System
Malignant neoplasm of middle lobe, bronchus or lung
Malignant neoplasm of main bronchus
Primary malignant neoplasm of pleura
Malignant neoplasm of upper lobe of lung
Malignant neoplasm of upper lobe, bronchus or lung

Non-SLE (n)

2
1

52
30

8
1

46
38

3
1

37
19

0
0
0
0
3

14
14
12
11
10

Cardiovascular System
Muscular System
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Figure 8. Number of malignancies by body system
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Results
A binary logistic model was used to describe the fit for using the covariates to
select the SLE and non-SLE cohorts found in CPRD. IPTW was the weight variable and
there were two levels of responses, yes (has cancer) or no (does not have cancer). The
regression parameters were estimated using Fischer’s scoring method. The total number
of observations read and used was 183,580. The unweighted SLE cohort yielded 3025
patients and 180,555 patients in the non-SLE cohort (Table 12).

Table 12
Unweighted SLE (1) and Non-SLE (0) Cohorts in CPRD
Table of LUPUS by CANCERFLAG
CANCERFLAG(CANCRFLAG)
0

1

Total

LUPUS(LUPUS)
0
1

Total

Frequency
Frequency

Frequency

178 98

2157

180555

2906

119

3025

181304

2276

183580

In the unweighted cohorts, the relative risk of developing cancer due to having
SLE was 3.39 (see Table 13).
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Table 13
Statistics for Table of LUPUS by CANCERFLAG (unweighted)
Estimates of the Relative Risk (Row1/Row2)
Type of Study
Case-Control
(Odds Ratio)

Value
3.3868

95% Confidence Limits
2.8059
4.088

Once the computer generated weights were applied, the SLE cohort weight was
18055.7 and 645580 in the non-SLE cohort (Table 14).

Table 14
IPTW weighted SLE (1) and Non-SLE (0) Cohorts in CPRD

CANCERFLAG (CANCERFLAG)
0

1

Total

195565

2472.89

198037

450015

15582.9

465598

645580

18055.7

663636

LUPUS(LUPUS)
0

Frequency

1

Frequency

Total

Frequency

In the weighted cohorts, the unadjusted relative risk of developing cancer due to
having SLE is 2.74 (see Table 15).
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Table 15
Statistics for Table of LUPUS by CANCERFLAG (weighted)

Estimates of the Relative Risk (Row1/Row2)
Type of Study
Case-Control (Odds Ratio)

Value
2.7385

95% Confidence Limits
2.6238
2.8581

An assessment of the fit of the binary logistic model against the data revealed that
it was a good fit as demonstrated by the values of the intercept only versus the intercept
and covariates in the three methods used to assess the model fit. Akaike Information
Criterion (AIC) was used for the comparison of non-nested models on the same sample
(University of California Los Angeles. 2015). The Schwarz Criterion (SC) and the AIC
both penalize for the number of predictors in the model and the smallest SC and AIC are
the most desired model (University of California at Los Angeles. 2015). The -2 Log L is
used to test hypotheses in nested models and there is no real value in the numbers
(UCLA. 2015). The intercept only column represents the response variable with no
predictors in the model whereas the intercept and covariates column represents criterion
statistics for the fitted model, which includes all independent models and the intercept
(Table 16) (UCLA. 2015). For each of the criterion used, the lower value of the intercept
and covariates versus the intercept only confirms that the binary logistic model used was
a good fit for the data.
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Table 16
Model Fit – SLE & Non-SLE (unweighted)

Criterion
AIC
SC
-2 Log L

Intercept Only
165773.2
165783.3
165771.21

Intercept and
Covariates
163109.3
163129.6
163105.3

With no adjustment for age, the predictor variable of SLE indicates that a patient
with SLE is 2.7 times more likely to develop cancer than is a non-SLE patient with 95%
Confidence Limits (Table 17).
Table 17
Odds Ratio Estimates-SLE

Effect
LUPUS

Point Estimate
2.738

95%Wald
Confidence Limits
2.623
2.857

Pr > ChiSq
<.0001

The fit of the binary logistic model was assessed with the variables of age. The
binary logistic model was again a good fit as demonstrated by the lesser value of the
intercept and covariates versus intercept only value for each of the three methods used to
assess the model fit, AIC, SC, and -2 Log L (see Table 18). The greater difference in the
intercept and the intercept wand covariates indicates that with the addition of age, the
model was an even better fit than without the weighted covariates.
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Table 18
Model Fit – SLE and Age

Criterion
AIC
SC
-2 Log L

Intercept Only
165773.2
165783.3
165771.21

Intercept and
Covariates
149047.2
149077.5
149041.2

With adjustment for age, the predictor variable of SLE indicates that a patient
with SLE is still 2.7 times more likely to develop cancer than is a non-SLE patient with
95% confidence limits (Table 19). Age was not a significant factor in whether the SLE
patients developed cancer.

Table 19
Odds Ratio Estimates-SLE & AGE

Effect
LUPUS

Point Estimate
2.669

95% Wald
Confidence Limits
2.556
2.788

AGE

1.052

1.051

1.053

Pr > ChiSq
<.0001
<.0001

All of the original covariates related to cancer development were not identifiable
in CPRD because of the limitations of using a database that was designed to collect
universal health information in the United Kingdom.
Odds ratio estimates were run to include age, contraception use, pregnancies,
obesity, and smoking history (Table 20). Having had a pregnancy had the greatest effect
on whether cancer developed when all the other variables were held constant. The next
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greatest effect on cancer development was having SLE, followed by obesity, use of oral
contraception, age, and then smoking. It was quite surprising that smoking actually
seemed to have a protective effect on cancer development. These effects are stated with
95% confidence limits that with repeated trials; we would obtain the same results for each
covariate. No additional post-hoc analyses were performed.
Table 20
Odds Ratio Estimates for Age, Contraception Use, Pregnancies, Obesity, and Smoking
History

Effect
Lupus
Age
Contraception
Pregnancy
Obesity
Smoking history

Point Estimate
2.906
1.06
1.602
3.146
2.476
0.793

95% Wald Confidence Limits
2.781
3.035
1.058
1.061
1.521
1.687
2.98
3.322
2.4
2.555
0.765
0.823

Pr > ChiSq
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

Summary
This study sought to assess the association of cancer development in patients with
SLE. In evaluating research question one, the risk of cancer development is increased in
SLE patients compared to non-SLE patients. In the weighted cohorts, the unadjusted
relative risk of developing cancer due to having SLE was 2.74. The greatest number of
malignancies was female specific cancers such as breast, uterus and cervix followed by
malignancies of the digestive system. This finding is congruent with findings from
previous research, that several cancers are thought to be increased in people with SLE as
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compared to persons without SLE (Bernatsky et al., 2005; Kiss et al., 2010; Parikh-Patel
et al., 2008).
The balance created by using the IPTW to select the SLE and non-SLE cohorts
attributed to a more accurate comparison of the risk of developing cancer between the
two groups. The exposure to similar disorders and concomitant medications controlled
for exposures that could have attributed to the risk of cancer development and biased the
assessment of the cancer risk. Weighting the variables to control the number and
similarity of variables in the patients in each cohort contributed to the balance of the
variables between the study participants and results in less bias that could be attributed to
medical history.
When assessing cervical cancer risk in SLE patients as compared to non-SLE
populations, the null hypothesis failed to be rejected. The number of cervical cancers
found in the non-SLE cohort (n = 88) were significantly greater than the number found in
the SLE cohort (n = 2). This finding appear to contradict findings by Kiss et al. (2010)
and Bernatsky et al. (2005), who reported cervical cancer to be increased in SLE patients.
The findings may appear to oppose previous findings because of the size of the
CPRD database versus the sample size used by Kiss et al. (2010) and Bernatsky et al.
(2005). This study had 3,025 SLE patients and 180, 555 non-SLE patients; Kiss et al.
(2010) had only 860 patients with SLE and Bernatsky et al. (2005) had only 1,545
patients with SLE. Both studies compared the rates found in their SLE patients to rates
found in the general population. In addition, in the Bernatsky et al. (2005) study, they
noted that women with SLE have an increased risk of cervical dysplasia and atypia on
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Pap testing as compared to non-SLE females. Cervical dysplasia and atypical pap tests do
not always result in cervical cancer. This study compared only primary cervical cancer,
not secondary malignancies, nor abnormal Pap tests. This study also compared non-SLE
females in CPRD only and not in the general population. The patients were also balanced
in terms of the types of other diagnoses and concomitant medications to which the two
groups had been exposed. These factors all contribute to the seemingly contradictory
findings in this study as compared to some previous studies.
In this chapter, deviations from the initial plan to use preselected covariates based
upon the literature review were explained along with the rationale for the use of an
alternative plan. Details of methods used to select and balance the two cohorts from
CPRD were explained in detail. Checks to ascertain that the models used were included
to confirm the appropriate fit of the model. Finally, findings from the various assessments
that were performed to assess the association of cancer development in SLE patients as
compared to non-SLE patients were presented. In Chapter 5, I will discuss the social
change implications of these findings, the limitations of this study, and future
recommendations for continued research to assess the association of cancer development
in SLE as compared to non-SLE patients.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this study was to assess whether there is an association between
cancer developments in patients with SLE as compared to non-SLE patients. A
propensity, score-matched, retrospective, cohort study among SLE and non-SLE female
patients identified in CPRD was used. Female SLE patients were matched with non-SLE
patients in CPRD. The matching was performed by using a high dimensional propensity
model. The high dimensional propensity model was used to assign weights to variables
based upon the analyses of common variables related to SLE and found in the database
(Schneeweiss et al., 2009). The covariates used to select the SLE and non-SLE cohorts
were diagnoses that were most commonly made in SLE patients and most commonly
associated prescriptions made to patients with SLE. The selected covariates were chosen
based on the frequency that they were found in the database for the selected population,
in this case SLE. The covariates, concurrent diagnoses and concomitant medications,
were then assimilated into a propensity score-based confounder adjustment model. The
application of an IPTW to the SLE and non-SLE cohorts rendered a SLE cohort of 3,025
and a non-SLE cohort of 180,555 patients.
Previous research in this area has been based upon small study samples, cohorts
that were not closed, which could increase the number of patients lost to follow-up, and
the studies have lacked definitive diagnosis dates for SLE in the participants (Bernatsky
et al., 2005; Parikh-Patel et al., 2008). As a result, previous studies were generally
underpowered to be able to determine conclusively whether a relationship exists between
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SLE and cancer (Bernatsky et al., 2005). In this study, I used a large, population-based
database to test the relationship between SLE and cancer.
Use of the high dimensional propensity model allowed the cohorts in the study to
be much better balanced than some of the studies that have been done in the past. The
balance that was created by allowing the computer to search the entire CPRD database
and select the most common diagnoses and concomitant medications that were assigned
to patients with a diagnosis of SLE decreased the potential for bias that could result from
selecting the non-SLE cohort based of age or age group. The balance in matching the
cohorts decreased the potential for bias that could result due to the use of certain
medications. The significant finding in the weighted cohorts was that the relative risk of
developing cancer due to having SLE was 2.74 (95% CL). Another significant finding
was that age was not a significant factor in whether the SLE patients developed cancer.
Interpretation of the Findings
The findings from this study confirm that cancers are increased in patients with
SLE as compared to persons without SLE. In this study, the greatest number of
malignancies was female-specific cancers such as breast, uterus, and cervix. The next
largest group of malignancies was in the digestive system. The cohorts in this study were
restricted to female only, and for that reason the fact that the greatest types of cancers
were female-specific can neither confirm nor refute previous findings regarding the types
of cancers increased in SLE patients.
As reported by the CDC (2014), age greater than 65 years is a risk factor for most
types of cancers. As a person ages, he or she is exposed to the multitude of elements,
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including both environmental and lifestyle factors, which are associated with increased
risk of general cancer development (CDC, 2014). This study could not confirm or
disconfirm whether age greater than 65 years resulted in a greater risk of developing
cancer. I did find it increasing that age did not increase the development of cancer. This
finding is in contradiction to findings by Extermann (2000) who found that increasing
age increases the likelihood of developing cancer of some type because of the longer
exposure to potential carcinogens in the environment, foods, and other factors.
Being overweight increases the risk of some cancers because of increased levels
of estrogens and insulin (Cancer Research United Kingdom, 2014). OR estimates obesity
had a 2.5 increased effect on whether cancer developed when all the other variables were
held constant. A full-term pregnancy before the age of 17 years as compared to a woman
who had her first pregnancy after the age of 25 years and women who have more than
three pregnancies were associated with an increase in the risk of cervical cancer
development (CDC, 2014). These two factors increase the risk of cervical cancer
development because they increase the chances of acquiring a HPV infection because of
the potential of the woman having unprotected sex with a greater number of sexual
partners (ACS, 2014). The hormonal changes associated with pregnancy may also
contribute to a weakened immune system and render the woman to susceptible to HPV
infection (ACS, 2014). The OR estimates that if the patient had a pregnancy, she has a
3.1 (95% CL) increased chance of cancer development when all the other variables were
held constant. In this study, any pregnancy was reported and not the number of
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pregnancies. For this reason, the ability to assess the impact that pregnancy has on cancer
development was not possible.
Use of estrogen-progestagen OCs over a 5-year or greater period may increase the
development of cervical cancer (CDC, 2014). Although HPV exposure is known to be the
most important cause of cervical cancer, when combined with long-term use of OCs, the
RR of cervical cancer development was increased as duration of use increased. Smith et
al. (2003) studied women with cervical cancer with no history of OC use (RR 1.9-2.2)
compared to women who had used OCs (RR 1.6-3.9) for more than 10 years and found
that the incidence of cervical cancer increased with longer use of OCs. OR estimated that
contraception use had 1.6 increased effects on whether cancer developed, when all the
other variables were held constant. In this study, the information regarding the amount of
time that the patient used an OC and whether it was estrogen progestogen-based was not
assessable; therefore, it is impossible to accept whether OC use affects the risk of cancer
development.
Smoking renders a person exposed to many cancer-causing chemicals that affect
multiple body organs when the chemicals are carried via the blood system to the organs.
The chemicals act to damage the DNA of cells and may contribute to the development of
multiple cancers (ACS, 2014). A history of tobacco use was a cancer risk factor in this
study and was measured as either yes or no. OR estimated that smoking had a protective
effect on whether cancer developed when all the other variables were held constant. This
outcome was not expected because it is not consistent with the knowledge base. Neither
CPRD nor HES provided enough details on smoking history to be able to assess this
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variable appropriately. In this study, the amount of time that the patient smoked was not
assessable; therefore, it is impossible to accept how smoking affects the risk of cancer
development based upon the results from this study.
Limitations of the Study
The validity of this study depended on the accuracy and reliability of the
information entered into the database. SLE is a difficult diagnosis to make and there may
have been a risk of including non-SLE patients. The most common area of bias occurred
in the collection of history of the patients admitted into the study. The study population
included females with SLE and female non-SLE patients. Patients with a diagnosis of
SLE were matched to non-SLE females using a high-dimensional propensity score. This
method of using a high-dimensional propensity model is one method to address bias that
can enter a study because of the history of the patients in the comparison groups. This
method decreased bias that could present itself due to the selection process. A lack of
consideration to the history of the patients, especially those factors that could lead to the
development of SLE decreased bias between the comparison groups. The propensity
score method of matching also addressed bias that was commonly a result of inclusion
and exclusion criterion for a study. Selection using propensity score matching ensures
that the comparison groups are equal in their covariates that could lead to the
development of SLE and cancer.
The use of data that had already been collected has limitations in that the research
questions must be tailored around the information that is available in the database. An
additional limitation associated with using CPRD could be whether the data that were

95
entered into the database were entered with accuracy and reliability. There is no
expectation that there is a difference in the accuracy of reporting between SLE and nonSLE patients. The Hospital Episode Statistics database was used for this study. The
validity of this study depended on the accuracy and reliability of the information entered
into the database. The most common areas of bias occur in the history of the patients
admitted into the study, the inclusion criterion used to select patients into the study, and
the methods used to analyze the study results (Gerhard, 2008).
Recommendations
The primary value of this study is that it used a large database to incorporate the
numerous factors that are thought to lead to the development of SLE and cancer, both
chronic diseases. There are many challenges in determining associations especially in
chronic diseases such as SLE and cancer. These two diseases involve multiple factors that
interact and result in their disease state. Consideration of the various factors that
contribute to the two diseases is necessary to measure an association of the two diseases.
The fact that both cancer and autoimmune diseases have been associated with diet, air
quality, exposure to certain drugs, and personal habits makes the study of an association
between the two diseases somewhat challenging. Studies completed to date have not
shown consistent relationships of cancer development in patients with SLE.
In this study, careful consideration was given to the multiple factors that play a
role in the development of SLE and in cancer. A large, population-based database was
used to assess the relationship between SLE and cancer in a large population. The design
of this study, and the methods to assess the findings were dynamic enough to allow for a
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detailed analysis that was easily understood. A propensity score-matched retrospective
cohort study among SLE and non-SLE female patients identified in CPRD was used to
assess the association of cancer development in patients with SLE will be conducted.
Non-SLE patients were matched with SLE patients in CPRD and then linked to an
additional database for information on the covariates.
Balance between the SLE and non-SLE cohorts was obtained by using variables
that were associated with patients with SLE to determine the treatment and non-treatment
cohorts. This method of cohort selection balanced the SLE and non-SLE cohorts and
balance between the study participants. I recommend that more studies to assess the
association of cancer development in SLE patients be conducted utilizing a propensity
score model to balance the study groups.
I further recommend that a database that contains more data that can be used to
assess disease severity be used to study the association of cancer in patients with SLE. A
focused medical history should be collected so that history such as age at first pregnancy
and number of pregnancies, use of oral contraceptives, tobacco use, and viruses such as
EBV/HPV can be assessed. Details of the medical history are essential in studying two
chronic non-communicable diseases such as SLE and cancer.
Implications
Positive social change refers to involvement in activities that make improvements
in the lives of individuals and communities locally and around the world. The goal of
social change is to incorporate strategies that allow the individuals in the target
population to maintain their dignity and self-worth. Positive social change results in
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improvements in the health of the target population as well as their overall quality of life.
The most important aspect of positive social change is that it gives individuals and
eventually groups the power to improve the world around them (Walden University,
2011). My research, to assess the association of cancer development in persons with SLE
disease, could promote positive social change by providing a better understanding of
variables that may impact cancer development in patients with SLE. Understanding
variables that can modify cancer risk can provide insight to factors that could possibly be
altered to decrease the development of cancer in persons with SLE.
An understanding of these associations provides valuable insight to factors that
can be altered to decrease the development of cancer in SLE patients. A matched
retrospective cohort study among SLE and non-SLE patients was conducted using the
propensity score methodology to help balance the differences between the comparison
groups. The propensity score methodology created a similar distribution of observed
baseline covariates between the two groups. The study outcomes could be used to
promote positive social change by reinforcing current recommendations for cancer
screenings in persons with SLE, which could enhance the ability to detect cancer early
enough to decrease mortality due to cancer in persons with SLE.
Stronger adherence to cancer screening recommendations could enhance the
ability to detect a cancer early enough so that treatment can be implemented that may
result in a higher likelihood to effectively eradicate the cancer and decrease mortality due
to cancer in persons with SLE. Results from this study could also equips persons with
SLE with scientifically-based knowledge that may enable them to make decisions
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regarding their care with a clearer understanding of the cancer risks inherent to persons
with SLE, particularly when factored with their knowledge of their personal familial risks
for cancer development.
Conclusion
In conclusion, better control of SLE flares has resulted in decreased deaths due to
SLE activity and people affected by the disease are living longer. The increase in the
lifespan of people with SLE has now shown that other chronic diseases are often the
cause of death for persons with SLE. As new models of studying diseases are developed,
they should be utilized as appropriate. Newer research models can assist in a better
understanding of the multifactorial causations of chronic diseases since they often are a
result of overlapping environmental, lifestyle, and everyday exposures. The economic
burdens caused by autoimmune diseases and cancers make them a major public health
concern. The increasing health-care burdens of both diseases must be better understood
so that improved and targeted programs to ease the economic burdens on the public
health system can be developed and implemented.
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